| 1 | 13:00-13:05 |
Opening Remarks |
|
||||||||
| 1 | 13:05-13:25 |
FRUSICA‑2 Study Opens a New Chapter for Previously Treated Renal Cell Carcinoma |
|
||||||||||||||
| 2 | 13:25-13:45 |
Stratified Therapy and Whole-Course Management: Building the Blueprint for Diagnosis and Treatment of Advanced Renal Cell Carcinoma |
|
||||||||||||||
| 3 | 13:45-14:05 |
Discussion |
|
||||||||||||||
| 1 | 14:05-14:25 |
Frontline Advances in Immunotherapy for Renal Cell Carcinoma |
|
||||||||||||||
| 2 | 14:25-14:45 |
New Insights into Perioperative Strategies for Renal Cell Carcinoma in the Immunotherapy Era |
|
||||||||||||||
| 3 | 14:45-15:05 |
Discussion |
|
||||||||||||||
| 1 | 15:05-15:10 |
Summary |
|
||||||||
| 1 | 16:00-16:15 |
Opening Remarks |
|
|||||||||||
| 1 | 16:15-16:25 |
Launch Ceremony of the 2027 National Project for Standardized Construction of Precision Diagnosis and Treatment and Recurrence Prevention of Urolithiasis |
|
|||||
| 2 | 16:30-16:40 |
Interpretation of the Chinese Expert Consensus on Metabolic Evaluation and Recurrence Prevention of Urolithiasis |
|
|||||
| 1 | 16:40-16:50 |
Patented Sustained-release Technology and Technical Breakthroughs of Potassium Citrate for Generic Consistency Evaluation |
|
|||||
| 2 | 16:50-17:10 |
Application of Potassium Citrate in Urolithiasis |
|
|||||
| 3 | 17:10-17:20 |
Case Sharing |
|
|||||
| 1 | 17:20-17:45 |
Discussion: 1. Metabolic Assessment: From Guidelines to Clinical Application 2. Nephrolithiasis Prevention: From Concept to Behavior 3. Multi-party Collaboration: From Consensus to Practice |
||||||||||||
| 2 | 17:45-18:00 |
Summary |
|
|||||||||||
| 1 | 14:00-14:10 |
Opening Remarks |
|
|||||||||||
| 2 | 14:10-14:20 |
Launch Ceremony of the CUA Prostate Cancer Abstract Reading Roadshow and the "Technique Meets Strategy" Series |
|
|||||||||||
| 3 | 14:20-14:30 |
Launch Ceremony: Aranote NRDL Inclusion and Release of DASL Clinical Trial Results |
|
|||||||||||
| 1 | 14:00-14:30 |
Congress Chairpersons |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2 | 14:00-14:30 |
Congress Presidium |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 1 | 14:30-14:50 |
The Evolution of Prostate Cancer Surgery |
|
||||||||||||||||||||
| 2 | 14:50-15:00 |
Discussion |
|
||||||||||||||||||||
| 3 | 15:00-15:20 |
Advances in Novel Hormonal Therapy in the Perioperative Setting (Speaker-selected title) |
|
||||||||||||||||||||
| 4 | 15:20-15:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 15:30-15:50 |
Conversion Therapy and CMI-related Topic |
|
||||||||||||||||||||
| 2 | 15:50-16:00 |
Discussion |
|
||||||||||||||||||||
| 1 | 16:00-16:20 |
Roundtable Discussion: Perioperative Treatment |
|
|||||||||||||||||
| 1 | 16:20-16:30 |
U-MBA Academy 2nd Anniversary Gala · Two Years, One Heart — United We Sail Far |
|||
| 1 | 16:30-16:45 |
Recent Advances in the Treatment of Prostate Cancer |
|
||||||||||||||||||||
| 2 | 16:45-17:00 |
Discussion |
|
||||||||||||||||||||
| 1 | 17:00-17:05 |
CUA Prostate Cancer Abstract 1 Reading |
|
|||||||||||||||||||||||
| 2 | 17:05-17:12 |
Discussion |
|
|||||||||||||||||||||||
| 3 | 17:12-17:17 |
CUA Prostate Cancer Abstract 2 Reading |
|
|||||||||||||||||||||||
| 4 | 17:17-17:24 |
Discussion |
|
|||||||||||||||||||||||
| 5 | 17:24-17:29 |
Journal Club: Study Three |
|
|||||||||||||||||||||||
| 6 | 17:29-17:36 |
Discussion |
|
|||||||||||||||||||||||
| 7 | 17:36-17:41 |
CUA Prostate Cancer Abstract 4 Reading |
|
|||||||||||||||||||||||
| 8 | 17:41-17:48 |
Discussion |
|
|||||||||||||||||||||||
| 9 | 17:48-18:00 |
Discussant |
|
|||||||||||||||||||||||
| 1 | 18:00-18:15 |
RWE Study Design and Considerations |
|
|||||
| 2 | 18:15-18:20 |
Summary |
|
|||||
| 1 | 13:35-13:50 |
Opening Remarks |
|
||||||||||||||||||||
| 2 | 13:35-13:50 |
Opening Remarks |
|
||||||||||||||||||||
| 3 | 13:50-14:02 |
Case Presentation 1 (Title TBD) |
|
||||||||||||||||||||
| 4 | 13:50-14:02 |
Expert Commentary 1 |
|
||||||||||||||||||||
| 5 | 14:02-14:14 |
Case Presentation 2 (Title TBD) |
|
||||||||||||||||||||
| 6 | 14:02-14:14 |
Expert Commentary 2 |
|
||||||||||||||||||||
| 7 | 14:14-14:26 |
Case Presentation 3 (Title TBD) |
|
||||||||||||||||||||
| 8 | 14:14-14:26 |
Expert Commentary 3 |
|
||||||||||||||||||||
| 9 | 14:26-14:38 |
Case Presentation 4 (Title TBD) |
|
||||||||||||||||||||
| 10 | 14:26-14:38 |
Expert Commentary 4 |
|
||||||||||||||||||||
| 11 | 14:38-14:50 |
Case Presentation 5 (Title TBD) |
|
||||||||||||||||||||
| 12 | 14:38-14:50 |
Expert Commentary 5 |
|
||||||||||||||||||||
| 13 | 14:50-15:02 |
Case Presentation 6 (Title TBD) |
|
||||||||||||||||||||
| 14 | 14:50-15:02 |
Expert Commentary 6 |
|
||||||||||||||||||||
| 15 | 15:02-15:14 |
Case Presentation 7 (Title TBD) |
|
||||||||||||||||||||
| 16 | 15:02-15:14 |
Expert Commentary 7 |
|
||||||||||||||||||||
| 17 | 15:14-15:26 |
Case Presentation 8 (Title TBD) |
|
||||||||||||||||||||
| 18 | 15:14-15:26 |
Expert Commentary 8 |
|
||||||||||||||||||||
| 19 | 15:26-15:30 |
Group Photo |
|
||||||||||||||||||||
| 20 | 15:30-15:35 |
Summary |
|
||||||||||||||||||||
| 1 | 16:05-16:10 |
Opening Remarks |
|
||||||||
| 1 | 16:10-16:35 |
New Targets for the Management of BPH/LUTS — Rethinking Therapeutic Strategies Based on Inflammatory Mechanisms |
|
|||||
| 2 | 16:35-16:55 |
Based on a Century of Evidence-Based Evolution— A Reappraisal of the Clinical Value of a Plant Extract |
|
|||||
| 1 | 16:55-17:15 |
Dancing with Time and Health — Thoughts on Chronic Disease Management in Elderly Patients with BPH |
|
|||||||||||||||||
| 2 | 17:15-17:40 |
Discussion |
|
|||||||||||||||||
| 1 | 17:40-18:00 |
Discussion |
|
||||||||||||||||||||
| 2 | 18:00-18:05 |
Summary |
|
||||||||||||||||||||
| 1 | 13:45-13:50 |
Opening Remarks |
|
||||||||||||||
| 1 | 13:50-14:10 |
Standardizing Long-Term ADT Management: Building a Foundational Strategy for Comprehensive Prostate Cancer Care |
|
|||||||||||||||||
| 2 | 14:10-14:30 |
Treatment Insights for Oligometastatic Prostate Cancer |
|
|||||||||||||||||
| 3 | 14:30-14:45 |
Discussion |
|
|||||||||||||||||
| 1 | 14:45-14:50 |
Case Scenario and Role Introduction |
|
||||||||||||||||||||||||||
| 2 | 14:50-15:05 |
Round 1: Decoding the Diagnosis |
|
||||||||||||||||||||||||||
| 3 | 15:05-15:20 |
Round 2: MDT Decision-Making |
|
||||||||||||||||||||||||||
| 4 | 15:20-15:35 |
Round 3: Patient-Centered Care |
|
||||||||||||||||||||||||||
| 5 | 15:35-15:40 |
Discussion |
|
||||||||||||||||||||||||||
| 6 | 15:40-15:45 |
Summary |
|
||||||||||||||||||||||||||
| 1 | 16:10-16:15 |
Opening Video |
||||||||||||
| 2 | 16:15-16:20 |
Opening Remarks |
|
|||||||||||
| 1 | 16:20-16:35 |
From Consensus to Action: Shaping a New Era of High-Quality Development in GU in China |
|
|||||||||||||||||
| 2 | 16:35-16:45 |
Leadership Dialogue on Development in GU in China |
|
|||||||||||||||||
| 1 | 16:45-17:00 |
Continuously Expanding the Boundaries of Surgery for RCC |
|
|||||
| 2 | 17:00-17:15 |
Standardized Management of Adverse Events in Systemic Therapy for mRCC |
|
|||||
| 1 | 17:25-17:45 |
From Consensus to Action: Advancing Practice in RCC |
|
||||||||||||||||||||
| 1 | 17:30-17:45 |
Paradigm Shift in Systemic Therapy for Advanced Prostate Cance |
|
|||||
| 1 | 17:45-18:00 |
From Consensus to Action: Advancing Practice in PC |
|
|||||||||||||||||
| 2 | 18:00-18:10 |
Summary |
|
|||||||||||||||||
| 1 | 13:30-13:40 |
Opening Remarks |
|
|||||||||||
| 1 | 13:40-13:55 |
Translational Medicine Empowering Drug Development |
|
||||||||||||||||||||||||||||||||||||||||||||
| 2 | 13:55-14:10 |
Urology Discipline Development and Operations Management at Renji Hospital |
|
||||||||||||||||||||||||||||||||||||||||||||
| 3 | 14:15-14:35 |
Patient-Centered Optimization and Practice of Multidisciplinary Team (MDT) Management in Urology |
|
||||||||||||||||||||||||||||||||||||||||||||
| 4 | 14:35-14:45 |
Discussion |
|
||||||||||||||||||||||||||||||||||||||||||||
| 1 | 14:45-15:05 |
New Advances in Global Uro-oncology Diagnosis and Treatment (2026) |
|
||||||||||||||||||||||||||||||||||||||
| 2 | 15:05-15:25 |
New Breakthroughs in Precision Diagnosis and Treatment for mHSPC Prostate Cancer |
|
||||||||||||||||||||||||||||||||||||||
| 3 | 15:25-15:35 |
Discussion |
|
||||||||||||||||||||||||||||||||||||||
| 1 | 15:35-15:40 |
Summary |
|
|||||||||||
| 1 | 15:50-15:55 |
Opening Remarks |
|
||||||||
| 1 | 15:55-16:20 |
Applications and Prospects of Urinary DNA Testing in the Whole-Course Management of Urothelial Carcinoma |
|
||||||||||||||
| 2 | 16:20-16:45 |
Real-World Data on Urinary DNA Testing |
|
||||||||||||||
| 3 | 16:45-17:05 |
Discussion1: How Can Urinary DNA Testing Be Integrated into the Whole-Course Management of Urothelial Carcinoma |
|
||||||||||||||
| 1 | 17:05-17:30 |
Evidence-Based Advances of PSMA PET in Precision Diagnosis and Treatment of Prostate Cancer: Staging Reassessment, Impact on Treatment Decisions, and the Trend toward Theranostics |
|
||||||||||||||
| 2 | 17:30-17:45 |
Discussion2: How Molecular Imaging Is Reshaping the Whole-Course Management Paradigm for Prostate Cancer |
|
||||||||||||||
| 1 | 17:45-17:50 |
Summary |
|
|||||
| 1 | 15:00-15:25 |
Opening Remarks |
|
|||||||||||||||||
| 1 | 15:25-15:45 |
From Evidence to Clinical Practice: Interpretation of the Expert Guidance on the Clinical Use of Enfortumab Vedotin in Urothelial Carcinoma |
|
|||||
| 2 | 15:45-16:05 |
Redefining First-Line Treatment: Enfortumab Vedotin Combination Therapy as a New SoC for La/mUC |
|
|||||
| 3 | 16:05-16:25 |
Redefining UC Care: Evolving Treatment Landscape and New Perspectives on Patient Management |
|
|||||
| 1 | 16:25-16:50 |
Discussion |
|
|||||||||||||||||||||||||||||||||||
| 1 | 16:50-17:10 |
Exploring current perceptions in mHSC: myths, evidence, and practice |
|
|||||
| 2 | 17:10-17:30 |
Shaping the Future: The Evolving Landscape of Prostate Cancer Treatment |
|
|||||
| 1 | 17:30-17:55 |
Discussion |
|
|||||||||||||||||||||||||||||
| 1 | 17:55-18:00 |
Summary |
|
||||||||||||||
| 1 | 13:00-13:05 |
Opening Remarks and Academic Inauguration |
|
||||||||
| 1 | 13:05-13:10 |
A New Chapter in Evidence and Long-Term Outcomes: Scientific Presentation of Long-Term Overall Survival (OS) Follow-up Results from the CHART Study |
|
|||||||||||||||||||||||||||||
| 1 | 13:10-13:20 |
Innovation with a Long-Term Vision: Advances in the Urologic Oncology R&D Pipeline and Clinical Development |
|
|||||
| 1 | 13:20-13:30 |
How Can Clinical Needs Guide Coordinated Progress in Urologic Oncology Innovation and Clinical Practice? |
|
|||||||||||||||||
| 1 | 13:30-13:45 |
Evidence-Based Standards: Updates to China and International Prostate Cancer Guidelines and Evolving Care Pathways |
|
|||||
| 1 | 13:45-14:00 |
Beginning with the End in Mind: Long-Term Benefits and Evolving Treatment Goals in Prostate Cancer |
|
|||||
| 1 | 14:00-14:15 |
From AI-Enhanced Fusion Biopsy to Transperineal Focal Therapy: The Evolving Role of UroFusion in Precision Prostate Cancer Care |
|
|||||
| 1 | 14:15-14:30 |
High-Risk Localized or Locally Advanced Prostate Cancer: Surgical Selection and Timing after Intensified Neo-adjuvant Therapy |
|
||||||||||||||
| 2 | 14:30-14:45 |
High Risk of Recurrence after Radical Prostatectomy: PSA Dynamics, PSMA PET, and Timing of Early Salvage Treatment |
|
||||||||||||||
| 3 | 14:45-14:55 |
Can Treatment Move Forward? Coordinating Perioperative Systemic Therapy, Local Treatment, and Recurrence Risk Management |
|
||||||||||||||
| 1 | 14:55-15:10 |
Newly Diagnosed High-Risk mHSPC: Doublet or Triplet Therapy? Individualized Selection Based on Disease Risk and Patient Characteristics |
|
|||||||||||||||||
| 2 | 15:10-15:25 |
From Rapid Tumor Control to Long-Term Management: Balancing Efficacy, Safety, Adherence, and Quality of Life in mHSPC |
|
|||||||||||||||||
| 3 | 15:25-15:35 |
Intensification Means More than Adding Treatments: Integrating Tumor Burden, Disease Risk, Fitness for Chemotherapy, and Long-Term Goals when Selecting Initial Therapy |
|
|||||||||||||||||
| 1 | 15:35-15:50 |
Earlier Testing: How HRR Gene Alteration Stratification Can Optimize First-Line Treatment Decisions in mCRPC |
|
||||||||||||||
| 2 | 15:50-16:05 |
From AR Pathway Inhibition to PARPi and AR Pathway Synergy: Evidence, Patient Selection, and Practical Considerations for Precision Combination Therapy |
|
||||||||||||||
| 3 | 16:05-16:15 |
How Can Precised First-Line Treatment in mCRPC Be Implemented while Preserving Subsequent Sequencing Options? |
|
||||||||||||||
| 1 | 16:15-16:30 |
Rethinking Treatment Decisions while Facing Multiple Clinical Challenges |
|
||||||||||||||
| 2 | 16:30-16:45 |
Practical Lessons in Moving from Individual Interventions to Comprehensive Care |
|
||||||||||||||
| 3 | 16:45-16:55 |
How Can an Actionable and Sustainable Comprehensive Care Plan Be Built for Heterogeneous Disease Courses and Patient Needs? |
|
||||||||||||||
| 1 | 16:55-17:00 |
Summary |
|
|||||
| 1 | 13:20-13:30 |
Opening Remarks |
|
|||||
| 1 | 13:30-14:00 |
Frontiers in the Management of Advanced Prostate Cancer: Current Insights and Future Perspectives |
|
|||||
| 1 | 14:00-14:05 |
Interactive Introduction |
|
|||||||||||
| 2 | 14:05-14:15 |
Chief Complaint, Present Illness, Examinations and Treatment Course |
|
|||||||||||
| 3 | 14:15-14:20 |
Audience Poll |
|
|||||||||||
| 4 | 14:20-14:30 |
Interactive Discussion-Which Tasks Can Be Handed Over to AI and Which Must Remain with Clinicians? |
|
|||||||||||
| 5 | 14:30-14:35 |
AI Scenario Demonstration |
|
|||||||||||
| 6 | 14:35-14:45 |
Expert Comments-Efficacy Verification of AI-Assisted Diagnosis and Treatment for Prostate Cancer |
|
|||||||||||
| 1 | 14:45-14:50 |
Case Presentation--Chief Complaint, Present Illness, Examinations and Treatment Course |
|
|||||||||||
| 2 | 14:50-15:00 |
Audience Poll |
|
|||||||||||
| 3 | 15:00-15:10 |
Interactive Discussion-Which Tasks Can Be Handed Over to AI and Which Must Remain with Clinicians? |
|
|||||||||||
| 4 | 15:10-15:15 |
AI Scenario Demonstration |
|
|||||||||||
| 5 | 15:15-15:25 |
Expert Comments-Efficacy Verification of AI-Assisted Diagnosis and Treatment for Prostate Cancer |
|
|||||||||||
| 1 | 15:25-15:30 |
Summary |
|
|||||
| 1 | 15:30-15:35 |
Opening Video |
|||||||||||||||
| 2 | 15:35-15:40 |
Opening Remarks |
|
||||||||||||||
| 1 | 15:40-16:00 |
The Role of Blue Light in TURBT: An International Perspective |
|
||||||||||||||
| 2 | 16:00-16:20 |
Clinical Value of Blue Light: Guidelines and Chinese Expert Consensus |
|
||||||||||||||
| 3 | 16:20-16:35 |
Discussion (3 Topics) |
|
||||||||||||||
| 1 | 16:35-16:50 |
Current Clinical Practice in China |
|
||||||||||||||
| 2 | 16:50-17:10 |
Combined Procedures Using Blue-Light Cystoscopy: Clinical Practice and Case Reviews |
|
||||||||||||||
| 3 | 17:10-17:25 |
Discussion (3 Topics) |
|
||||||||||||||
| 4 | 17:25-17:30 |
Summary |
|
||||||||||||||
| 1 | 13:40-14:00 |
Opening Remarks |
|
|||||||||||
| 1 | 14:00-14:20 |
Single-port robot-assisted Partial Nephrectomy and Prostatectomy |
|
|||||
| 2 | 14:20-14:40 |
Single-port robot-assisted retroperitoneal partial nephrectomy |
|
|||||
| 3 | 14:40-15:00 |
Single-port robot-assisted extraperitoneal radical prostatectomy |
|
|||||
| 4 | 15:00-15:20 |
Single-port robot-assisted transvesical simple prostatectomy |
|
|||||
| 5 | 15:20-15:35 |
Discussion-How should single-port versus multi-port surgical strategies be selected? |
|
|||||
| 1 | 15:35-15:40 |
Summary |
|
|||||
| 1 | 16:10-16:20 |
Opening Remarks |
|
||||||||
| 1 | 16:20-16:30 |
Scientific Presentation-Urowell Multicenter Clinical Trial Results |
|
|||||
| 1 | 16:30-16:45 |
A New Paradigm in Minimally Invasive BPH Treatment: From Tissue Resection to Functional Preservation |
|
|||||||||||
| 2 | 16:45-16:55 |
Discussion |
|
|||||||||||
| 3 | 16:55-17:10 |
Rejuvenating the Gland: The Theoretical Framework and Clinical Application of PUL |
|
|||||||||||
| 4 | 17:10-17:20 |
Discussion |
|
|||||||||||
| 5 | 17:20-17:35 |
Key Operative Points of PUL and Experience Sharing |
|
|||||||||||
| 6 | 17:35-17:45 |
Discussion |
|
|||||||||||
| 1 | 17:45-18:05 |
Discussion:Median Lobe Enlargement, Large-Volume Prostate, Small-Volume Prostate: What are the clinical application boundaries of PUL? |
|
|||||||||||||||||
| 1 | 18:05-18:10 |
Summary |
|
|||||
| 1 | 13:30-13:35 |
Opening Remarks |
|
|||||
| 1 | 13:35-13:45 |
Sharing of rosette suture technique in partial nephrectomy |
|
||||||||||||||||||||
| 2 | 13:45-13:55 |
Application of split robot in prostate surgery |
|
||||||||||||||||||||
| 3 | 13:55-14:05 |
Innovative technology and development of urinary tract reconstruction |
|
||||||||||||||||||||
| 4 | 14:05-14:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 14:30-14:40 |
Modified single-port robotic radical prostatectomy(pf-ssRARP) |
|
|||||||||||||||||||||||
| 2 | 14:40-14:50 |
Exploration and practice of application from single-port Laparoscopy to robot-assisted single-port Laparoscopy (MR-LESS) in urology |
|
|||||||||||||||||||||||
| 3 | 14:50-15:00 |
Urinary diversion for the patient’s quality of life |
|
|||||||||||||||||||||||
| 4 | 15:00-15:25 |
Discussion |
|
|||||||||||||||||||||||
| 1 | 15:25-15:30 |
Summary |
|
|||||
| 1 | 16:10-16:20 |
Opening Remarks |
|
|||||||||||
| 1 | 16:20-16:40 |
Advancing Through Evidence, Balancing with Precision: Research Progress and Clinical Decision-Making in First-Line Targeted Therapy Plus Immunotherapy for Advanced ccRCC |
|
|||||
| 2 | 16:40-17:00 |
Anlotinib plus Benmelstibart as First-Line Therapy for Renal Cell Carcinoma: Safety Management and Dose Optimization |
|
|||||
| 1 | 17:00-18:00 |
Discussion: Topic 1 Topic 2 |
|
|||||||||||||||||||||||||||||||||||||||||
| 1 | 18:00-18:10 |
Summary |
|
|||||||||||
| 1 | 12:00-12:10 |
Opening Remarks |
|
||||||||
| 1 | 12:10-12:30 |
Bone-Protective Therapy for Bone Metastases in Prostate Cancer: Initiating Early Intervention at the Asymptomatic Stage |
|
||||||||||||||
| 2 | 12:30-12:50 |
Discussion:1.What Are the Benefits of Early Initiation of Bone-Protective Therapy in Asymptomatic Patients with Prostate Cancer Bone Metastases? 2.What Insights Does the PEACE-3 Study Provide Regarding the Combination of Bone-Targeted Agents (BTAs) with Radionuclide and Endocrine Therapies? |
|
||||||||||||||
| 1 | 12:50-13:00 |
Summary |
|
||||||||
| 1 | 16:00-16:05 |
Opening Remarks |
|
||||||||
| 1 | 16:05-16:20 |
Spotlight on the Cutting Edge: Recent Advances in the Diagnosis and Treatment of BPH/LUTS |
|
|||||||||||||||||
| 2 | 16:20-16:35 |
Interpretation of the 2026 CUA Guidelines on Benign Prostatic Hyperplasia |
|
|||||||||||||||||
| 3 | 16:35-16:45 |
Background and Significance of the Development of the Chinese Expert Consensus on the Diagnosis and Treatment of Underactive bladder |
|
|||||||||||||||||
| 4 | 16:45-16:55 |
Interpretation of the Chinese Expert Consensus on the Diagnosis and Treatment of Bladder Hypofunction |
|
|||||||||||||||||
| 5 | 16:55-17:05 |
Discussion |
|
|||||||||||||||||
| 1 | 17:05-17:20 |
Development and Application of Noninvasive Precision Subtyping Technology for Primary Aldosteronism |
|
||||||||||||||
| 2 | 17:20-17:35 |
Surgical Considerations of Retroperitoneal Approach for Right Renal Carcinoma in Situs Inversus Totalis |
|
||||||||||||||
| 3 | 17:35-17:50 |
The Drum Tower’s Experience with Thousand Cases of Rezūm Therapy |
|
||||||||||||||
| 4 | 17:50-18:00 |
Discussion |
|
||||||||||||||
| 5 | 18:00-18:05 |
Summary |
|
||||||||||||||
| 1 | 13:45-13:55 |
Opening Remarks |
|
||||||||
| 1 | 13:55-14:10 |
Implementing a European Telesurgery Collaborative Network: Bringing Expertise and High- Standard Outcomes to Every Patient |
|
|||||||||||||||||||||||
| 2 | 14:10-14:25 |
Advanced training program for RARP Toumai multiport |
|
|||||||||||||||||||||||
| 3 | 14:25-14:40 |
Building a Sustainable Robotic Surgery Ecosystem: The Hospital’s Journey, Strategy and Vision |
|
|||||||||||||||||||||||
| 4 | 14:40-14:55 |
Retzius-Sparing Robotic Radical Prostatectomy: Lessons from Over 700 Cases — Functional Excellence Without Oncological Compromise? |
|
|||||||||||||||||||||||
| 5 | 14:55-15:10 |
Robotic Telesurgery :A New Era of Mature Remote Surgical Practice |
|
|||||||||||||||||||||||
| 6 | 15:10-15:25 |
Technical Modification of RCC with IVC Thrombus :Expriences from 400 + Robotic Cases in Single Chinese Center Since 2021. |
|
|||||||||||||||||||||||
| 7 | 15:25-15:40 |
Discussion |
|
|||||||||||||||||||||||
| 1 | 15:40-15:45 |
Summary |
|
|||||
| 1 | 13:40-13:45 |
|
|
|||||
| 2 | 13:45-13:50 |
|
|
|||||
| 3 | 13:50-13:55 |
|
|
|||||
| 4 | 13:55-14:00 |
|
|
|||||
| 5 | 14:00-14:05 |
|
|
|||||
| 6 | 14:05-14:10 |
|
|
|||||
| 1 | 14:10-14:25 |
From Clinical Question to International Publication: What Urology Editors Look For |
|
||||||||||||||
| 2 | 14:25-14:40 |
|
|
||||||||||||||
| 3 | 14:40-14:55 |
|
|
||||||||||||||
| 1 | 14:55-15:25 |
|
|
||||||||||||||
| 2 | 15:25-15:30 |
|
|||||||||||||||
| 1 | 09:10-09:30 |
How to Be a Good Surgeon |
|
|||||||||||||||||
| 2 | 09:30-09:50 |
Surgery in the Age of AI: Where Are We Headed? |
|
|||||||||||||||||
| 3 | 09:50-10:05 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 10:05-10:20 |
Artificial Intelligence - Blessing or Curse for The Urologists? |
|
|||||||||||||||||
| 2 | 10:20-10:35 |
Urological training in the Digital Era: Challenges and Benefits |
|
|||||||||||||||||
| 3 | 10:35-10:50 |
Optimizing urinary outcomes after radical prostatectomy |
|
|||||||||||||||||
| 4 | 10:50-11:05 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 11:05-11:20 |
cTURBT Combined With PLND and Targeted Therapy Plus Immunotherapy as a Comprehensive Radiotherapy-Free Bladder-Sparing Strategy: A Prospective, Multicenter, Single-Arm Clinical Trial in HER2-Overexpressing MIBC |
|
|||||||||||||||||
| 2 | 11:20-11:35 |
redefining the Perioperative treatment landscape for MIBC |
|
|||||||||||||||||
| 3 | 11:35-11:50 |
Reflections on Optimizing Treatment Regimens for Chinese Patients with mHSPC |
|
|||||||||||||||||
| 4 | 11:50-12:05 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 12:05-12:15 |
Minimal invasive treatment of renal cell carcinoma with IVC thrombus |
|
|||||||||||||||||
| 2 | 12:15-12:25 |
CUA Urinary Tract Reconstruction Committee: Buccal Mucosal Graft Multicenter Study and Platform Development |
|
|||||||||||||||||
| 3 | 12:25-12:35 |
Reinvestigation of Microsurgical Varicocelectomy Based on Anatomical Findings |
|
|||||||||||||||||
| 4 | 12:35-12:45 |
The innovation treatment of Pediatric Bladder Outlet Obstruction: 301 Experience |
|
|||||||||||||||||
| 5 | 12:45-13:00 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 13:00-13:10 |
Target-Driven, Evidence-Based Breakthroughs: AKT Inhibitors Open a New Chapter in Targeted Therapy for Prostate Cancer |
|
|||||||||||||||||
| 2 | 13:10-13:20 |
Robot-Assisted Radical Prostatectomy Without Prior Biopsy in Patients Selected by Concordant mpMRI and PSMA PET/CT Positivity: Interim Analysis of a Prospective Multicenter Randomized Controlled Trial |
|
|||||||||||||||||
| 3 | 13:20-13:30 |
Differential Treatment Response of Bladder Cancer: From Clinical Trial Findings to CBCC Real-World Exploration |
|
|||||||||||||||||
| 4 | 13:30-13:40 |
Efficacy and Safety of Cyclosporine A for Bladder Pain Syndrome/Interstitial Cystitis with Hunner Lesions |
|
|||||||||||||||||
| 5 | 13:40-13:55 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 13:55-14:05 |
AI in Urolithiasis: What Can It Do? |
|
|||||||||||||||||
| 2 | 14:05-14:15 |
The application of artificial intelligence in urodynamic diagnosis evaluation and closed-loop neuromodulation therapy. |
|
|||||||||||||||||
| 3 | 14:15-14:25 |
Multimodal Image Fusion-Guided Precise Navigation for Laser Ablation Therapy of Prostate Cancer |
|
|||||||||||||||||
| 4 | 14:25-14:35 |
A Pathology Foundation Model Driving Full-Process Management of Prostate Cancer |
|
|||||||||||||||||
| 5 | 14:35-14:50 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 14:50-15:00 |
Screening and Treatment for Hypogonadism: The Advantages of Using Gels |
|
|||||||||||||||||
| 2 | 15:00-15:10 |
CXCR4 receptor imaging-based surgical classification (CRISC) system: a novel subtyping system for guiding surgical management of primary aldosteronism. |
|
|||||||||||||||||
| 3 | 15:10-15:20 |
Analysis of a Multicenter Randomized Controlled Clinical Trial of Water Vapor Thermal Ablation System for Benign Prostatic Hyperplasia |
|
|||||||||||||||||
| 4 | 15:20-15:30 |
Efficacy and Safety of ¹⁷⁷Lu-PSMA-617 Combined with ADT and ARPI in PSMA+ mHSPC: A Subgroup Analysis of Chinese Population from the PSMAddition Trial |
|
|||||||||||||||||
| 5 | 15:30-15:45 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 15:45-15:55 |
Stable Disease Control for Long-term Survival: Redefining the Management Goals of mPC |
|
|||||||||||||||||
| 2 | 15:55-16:05 |
Phase Results and Iterative Updates of the Research Project on the Current Status and Awareness of Non-Complex Urinary Tract Infection Treatment in China |
|
|||||||||||||||||
| 3 | 16:05-16:15 |
Development of a Standardized Care and Tiered Referral Framework for Upper Tract Urothelial Carcinoma in Primary and Secondary Healthcare Settings in China |
|
|||||||||||||||||
| 4 | 16:15-16:25 |
Predictive Analysis of Urinary Incontinence Recovery Trajectories After Robot-Assisted Radical Prostatectomy: A Single-Center Real-World Study |
|
|||||||||||||||||
| 5 | 16:25-16:40 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 16:40-16:50 |
Preliminary Exploration of Kidney Xenotransplantation: The Chinese Experience |
|
|||||||||||||||||
| 2 | 16:50-17:00 |
MetaFlow Targeted Waterjet Resection System for the Treatment of Benign Prostatic Hyperplasia: A Prospective, Multicenter, Randomized Controlled Noninferiority Trial MetaFlow |
|
|||||||||||||||||
| 3 | 17:00-17:10 |
Novel CAR-T Therapy for Advanced Refractory Prostate Cancer |
|
|||||||||||||||||
| 4 | 17:10-17:25 |
Discussion and Comments |
|
|||||||||||||||||
| 1 | 08:00-08:05 |
Opening Remarks |
|
|||||
| 2 | 08:05-08:10 |
Opening Remarks |
|
|||||
| 3 | 08:10-08:15 |
Opening Remarks |
|
|||||
| 1 | 08:15-08:27 |
FANS Mini PCNL |
|
||||||||||||||
| 2 | 08:27-08:39 |
Hot Topics in the Diagnosis and Treatment of Complex Upper Urinary Tract Stones: Progress and Preliminary Exploration |
|
||||||||||||||
| 3 | 08:39-08:51 |
Chinese Expert Consensus on the Prevention and Management of Ureteral Stricture After Ureteroscopic Lithotripsy |
|
||||||||||||||
| 4 | 08:51-09:03 |
Mechanistic Validation of the Renal Tubular Injury Disease-Cluster Theory in Calcium Oxalate Nephrolithiasis: Dysregulated Phenylalanine Metabolism Injures Renal Tubules and Promotes Stone Formation |
|
||||||||||||||
| 5 | 09:03-09:15 |
Hot Topics in Minimally Invasive Treatment of Urolithiasis |
|
||||||||||||||
| 6 | 09:15-09:30 |
Discussion |
|
||||||||||||||
| 1 | 09:30-09:40 |
From Fluoroscopy to Ultrasound-Guided PCNL: Howto Make It Possible |
|
||||||||||||||
| 2 | 09:40-09:50 |
What is the Future for PCNL in the ERA of FANS |
|
||||||||||||||
| 3 | 09:50-10:00 |
Management of Lower Pole Stones |
|
||||||||||||||
| 4 | 10:00-10:10 |
Asymptomatic Non Obstructing Calyceal Stone: Treat or not to treat ! |
|
||||||||||||||
| 5 | 10:10-10:20 |
New Challenges PCNL: Technology Leads the Way |
|
||||||||||||||
| 6 | 10:20-10:30 |
Laser Applications in Endourology: Settings for Efficient Lithotripsy and BPH |
|
||||||||||||||
| 7 | 10:30-10:40 |
Discussion |
|
||||||||||||||
| 1 | 10:40-10:50 |
Development of a Novel Polymer-Based Material for Targeted Intervention in Sepsis |
|
||||||||||||||
| 2 | 10:50-11:00 |
Role and Mechanism of SIRT5-Mediated Desuccinylation of ACAA2 in Regulating Fatty Acid Oxidation in Renal Tubular Epithelial Cells During Calcium Oxalate Nephrolithiasis |
|
||||||||||||||
| 3 | 11:00-11:10 |
Development and Clinical Application of Super Multi-tract Minimally Invasive Percutaneous Nephrolithotomy (SMP-MPCNL) |
|
||||||||||||||
| 4 | 11:10-11:20 |
Quality Control of Etiological Diagnostic Techniques for Urolithiasis |
|
||||||||||||||
| 5 | 11:20-11:30 |
Application of Vascular Visualization Technology in PCN |
|
||||||||||||||
| 6 | 11:30-11:40 |
Molecular Characterization of a Multicenter Chinese Cohort of Cystine Stone Disease |
|
||||||||||||||
| 7 | 11:40-11:50 |
Preliminary Exploration of Real-World Studies on the Occurrence and Intervention of Urolithiasis |
|
||||||||||||||
| 8 | 11:50-12:00 |
Discussion |
|
||||||||||||||
| 1 | 13:30-13:40 |
Opening Remarks |
|
|||||
| 1 | 13:40-13:48 |
Multiscopic Combined Approaches for Complex Renal Stones in the New Era: Experience Sharing |
|
||||||||||||||
| 2 | 13:48-13:56 |
Development and Clinical Application of a Flexible Ureteroscopy Robot |
|
||||||||||||||
| 3 | 13:56-14:04 |
Use of Various Tubes and Access Channels in Percutaneous Nephrolithotomy |
|
||||||||||||||
| 4 | 14:04-14:12 |
Multicenter Clinical Study Results of the Vortex-Assisted Lithotripsy and Stone-Clearance System |
|
||||||||||||||
| 5 | 14:12-14:20 |
Preliminary Study of a Vortex-Assisted Intelligent Lithotripsy and Stone-Clearance System Versus Intelligent Pressure-Controlled FANS Flexible Ureteroscopy for Complex Renal Stones |
|
||||||||||||||
| 6 | 14:20-14:28 |
Mechanistic Study of Bacteroides fragilis-BSH in Inhibiting Calcium Oxalate Stone Formation via Regulation of Gut Bile Acid Metabolism |
|
||||||||||||||
| 7 | 14:28-14:36 |
Discussion |
|
||||||||||||||
| 1 | 14:36-14:44 |
Application of Nanozymes in the Prevention and Treatment of Renal Calcium Oxalate Stones |
|
||||||||||||||
| 2 | 14:44-14:52 |
Hydroxyapatite-induced IL6+ fibroblasts recruit GPNMB+ Macrophages to exacerbate Randall’s plaques |
|
||||||||||||||
| 3 | 14:52-15:00 |
Magnetic Field-Programmed FeCo Nanochains Drive Magnetomechanical-Thermal Synergistic Weakening and Minimally Invasive Lithotripsy of Calcium Oxalate Renal Pelvic Stones |
|
||||||||||||||
| 4 | 15:00-15:08 |
Multi-Omics Analysis Reveals That Isolithocholic Acid Promotes Calcium Oxalate Stone Formation via PARP1-Mediated Parthanatos |
|
||||||||||||||
| 5 | 15:08-15:16 |
Association Between Artificial Sweetener Intake and Kidney Stone Risk and an Aspartame-Based Mechanistic Investigation: A Study Integrating a Prospective Cohort and a Calcium Oxalate Nephrolithiasis Animal Model |
|
||||||||||||||
| 6 | 15:16-15:24 |
Current Status and Future of Robot-Assisted Flexible Ureteroscopic Lithotripsy |
|
||||||||||||||
| 7 | 15:24-15:32 |
Discussion |
|
||||||||||||||
| 1 | 15:32-15:40 |
Etiology and Pathogenesis of Infection-Related Staghorn (Struvite) Stones and Principles of PCNL Management and Follow-up |
|
||||||||||||||
| 2 | 15:40-15:48 |
Clinical Efficacy of Flexible Negative-Pressure Suction Sheath-Assisted Flexible Ureteroscopy Versus Percutaneous Nephrolithotomy for 2–4 cm Upper Urinary Tract Stones |
|
||||||||||||||
| 3 | 15:48-15:56 |
Vortex-Assisted Novel Flexible Ureteroscopy Combined with Holmium Laser for Renal Stones Under Local Anesthesia in the Split-Leg Supine Position: A 31-Case Series |
|
||||||||||||||
| 4 | 15:56-16:04 |
Brief Apnea to Control Renal Motion During Flexible Ureteroscopic Laser Lithotripsy: A Prospective Randomized Controlled Trial |
|
||||||||||||||
| 5 | 16:04-16:12 |
A Novel BTCH-PSCS Imaging Grading System for Medullary Sponge Kidney Stones: Evaluation of Disease Characteristics and Benefits of Surgical Treatment |
|
||||||||||||||
| 6 | 16:12-16:20 |
Calyceal Forniceal Puncture vs Transmedullary Puncture: How Should We Choose? |
|
||||||||||||||
| 7 | 16:20-16:28 |
Discussion |
|
||||||||||||||
| 1 | 16:28-16:36 |
Comparative Efficacy of Retroperitoneoscopic Ureterolithotomy and Flexible Ureteroscopic Holmium Laser Lithotripsy for Complex Upper Ureteral Stones |
|
||||||||||||||
| 2 | 16:36-16:44 |
Efficiency and Safety of FANS Technology Based on a Dual-Laser Energy Platform: From In Vitro Experiments to Clinical Practice |
|
||||||||||||||
| 3 | 16:44-16:52 |
Lactoferrin Promotes Ectopic Calcification of Renal Interstitial Fibroblasts via the IGF-1/IGFBP2 Signaling Pathway |
|
||||||||||||||
| 4 | 16:52-17:00 |
The AR/miR-185-5p/TGF-β Axis in Renal Tubular Epithelial Cells Mediates Hyperuricemia-Induced Kidney Stone Formation by Impairing Macrophage Recruitment and M2 Polarization |
|
||||||||||||||
| 5 | 17:00-17:08 |
Selenium Attenuates Oxalate-Induced Renal Injury and Ferroptosis by Regulating YAP1 Ubiquitination and Degradation |
|
||||||||||||||
| 6 | 17:08-17:16 |
Discussion |
|
||||||||||||||
| 1 | 17:16-17:24 |
Auricular Acupuncture Combined with NSAIDs for Rapid Relief of Renal Colic Caused by Urolithiasis: A Single-Center Prospective Randomized Controlled Trial |
|
||||||||||||||
| 2 | 17:24-17:32 |
An End-to-End Risk Stratification Tool for the Prevention and Management of Ureteral Stricture After Ureteroscopic Lithotripsy |
|
||||||||||||||
| 3 | 17:32-17:40 |
Clinical Value of a Self-Developed Angled-Outlet Flexible Ureteroscope (“Flying Fox Scope”) for Lower-Pole Stones in Horseshoe Kidneys |
|
||||||||||||||
| 4 | 17:40-17:48 |
Preoperative Double-J Stenting Combined with FANS Reduces Ureteral Access Sheath-Related Injury and Postoperative Double-J Stent Duration: A Single-Center Prospective Randomized Controlled Trial |
|
||||||||||||||
| 5 | 17:48-17:56 |
Experimental Study of an ROS-Responsive Ureteral Stent Coating Delivery System Based on Target Screening in Clinical Samples for the Prevention of Ureteral Stricture |
|
||||||||||||||
| 6 | 17:56-18:04 |
Comparative Study of Intelligent Pressure-Controlled Retrograde Intrarenal Surgery and Mini-Percutaneous Nephrolithotomy for 2–3 cm Renal Stones |
|
||||||||||||||
| 7 | 18:04-18:12 |
Discussion |
|
||||||||||||||
| 1 | 08:00-08:05 |
Opening Remarks |
|
|||||
| 1 | 08:05-08:20 |
Robotic Surgery in Female Functional Urology: Expanding the Boundaries |
|
|||||
| 2 | 08:20-08:35 |
TBD |
|
|||||
| 3 | 08:35-08:50 |
Robotic Colposacropexy Surgical Technique for the Treatment of Pelvic Organ Prolapse |
|
|||||
| 4 | 08:50-09:05 |
Impact of Transvaginal Natural Orifice Transluminal Endoscopic Nephrectomy on Sexual Function in Chinese Women: A Retrospective Cohort Study |
|
|||||
| 1 | 09:05-09:17 |
Outcomes of Single-Layer Circular Vaginal Flap Repair for Vesicovaginal Fistula at Different Surgical Timings |
|
|||||
| 2 | 09:17-09:29 |
Clinical Outcomes of “Dual-Plane Repair” for Pelvic Organ Prolapse Complicated by Stress Urinary Incontinence |
|
|||||
| 3 | 09:29-09:41 |
Comparison of Ultrasound Guidance and Fluoroscopic Localization in Stage I Sacral Neuromodulation: A Multicenter Retrospective Study of 400 Cases |
|
|||||
| 4 | 09:41-09:53 |
Efficacy and Safety of Submucosal Intravesical Platelet-Rich Plasma Injection for Refractory Interstitial Cystitis/Bladder Pain Syndrome |
|
|||||
| 1 | 09:53-10:03 |
Experience in Repair and Reconstruction of Female Urethral Stricture |
|
|||||
| 2 | 10:03-10:13 |
Application of Bladder Anterior Wall Flap Urethroplasty in Malignant Female Urethral Diverticulum |
|
|||||
| 3 | 10:13-10:23 |
Clinical Outcomes of Transvaginal Mid-Urethral Sling Combined with the Kelly Plication Technique: A Single-Center Report of 37 Cases |
|
|||||
| 4 | 10:23-10:33 |
Comparison of Surgical Procedures for Urinary Incontinence: A 10-Year Single-Center Retrospective Study |
|
|||||
| 1 | 10:33-10:43 |
Clinical Characteristics and Prognostic Value of Pelvic-Perineal Pain in Women with BPS/IC |
|
|||||
| 2 | 10:43-10:53 |
Efficacy of Combined Surgical and Pharmacological Treatment in Women with Detrusor Underactivity and Bladder Neck Obstruction: An Analysis Stratified by Post-Void Residual Volume |
|
|||||
| 3 | 10:53-11:03 |
Application of Individualized Nursing Care Under the ERAS Concept in Intravesical Botulinum Toxin Injection |
|
|||||
| 4 | 11:03-11:13 |
Development of a Diagnostic Model for Chronic Inflammatory Bladder Diseases in Women Based on Urodynamic and Inflammatory Markers |
|
|||||
| 1 | 11:13-11:23 |
Widened T-Shaped Sling Combined with Levator Ani and Perineal Body Reconstruction for Concomitant Stress Urinary Incontinence and Cystocele: A 2-Year Outcome Study |
|
|||||
| 2 | 11:23-11:33 |
Application of AI Combined with Robotic Technology in Female Urology |
|
|||||
| 3 | 11:33-11:43 |
GNRH family genes contributed to gender-specific disparity of bladder cancer prognosis through exerting opposite regulatory roles between females and males |
|
|||||
| 4 | 11:43-11:53 |
Individual and Co-exposure Exposure to Perchlorate, Nitrate, and Thiocyanate and Stress Urinary Incontinence in the U.S. Population: The Predominant Role of Thiocyanate |
|
|||||
| 5 | 11:53-12:03 |
|
|
|||||
| 1 | 13:00-13:30 |
Controversies with Testosterone Replacement Therapy |
|
|||||
| 1 | 13:30-13:35 |
Opening Remarks |
|
|||||
| 1 | 13:35-13:50 |
Mechanism and potentials of microenergy acoustic pulse therapy |
|
||||||||||||||
| 2 | 13:50-14:05 |
Leonardi Ejaculation Sparing Technique |
|
||||||||||||||
| 3 | 14:05-14:20 |
Original RASP ejaculation sparing technique following the anatomical premises of the LEST |
|
||||||||||||||
| 4 | 14:52-15:04 |
Discussion |
|
||||||||||||||
| 1 | 14:35-14:43 |
Development and Validation of an AI-Based Model for Sperm Viability Analysis |
|
||||||||||||||
| 2 | 14:43-14:51 |
A Single Dose of Dapoxetine Suppresses Functional Connectivity of the Subcallosal Cingulate Cortex in Patients with Premature Ejaculation: A Resting-State fMRI Study |
|
||||||||||||||
| 3 | 14:51-14:59 |
Diagnostic Value of Serum Total Testosterone, Free Testosterone, and Insulin-Like Peptide 3 (INSL3) for Late-Onset Hypogonadism |
|
||||||||||||||
| 4 | 14:59-15:07 |
Neural Circuit Basis of Stress-Induced Downregulation of Testosterone Synthesis: Insights from the Brain–Testis Axis |
|
||||||||||||||
| 5 | 15:07-15:19 |
Discussion |
|
||||||||||||||
| 1 | 15:19-15:27 |
Experience with Modified Devine Surgery for Concealed Penis |
|
||||||||||||||
| 2 | 15:27-15:35 |
Surgical Approach Selection and Perioperative Management of Penile Lengthening in Patients with Lower Abdominal Obesity: Experience Sharing |
|
||||||||||||||
| 3 | 15:35-15:43 |
Precision Perioperative Management of Inflatable Penile Prosthesis Implantation and Strategies to Improve Patient Satisfaction |
|
||||||||||||||
| 4 | 15:43-15:51 |
Surgical Experience with Penile Prosthesis Implantation after Anterolateral Thigh Flap Phalloplasty |
|
||||||||||||||
| 5 | 15:51-16:03 |
Discussion |
|
||||||||||||||
| 1 | 16:03-16:11 |
Single-Cell Molecular Pathology Atlas and Pathological Mechanisms of Azoospermia Caused by Cryptorchidism |
|
||||||||||||||
| 2 | 16:11-16:19 |
Testis-Sparing Surgery Deserves Greater Attention: A Single-Center Analysis of 121 Patients with Testicular Tumors |
|
||||||||||||||
| 3 | 16:19-16:27 |
Plane-Based Surgical Concept for Modified Laparoscopic Inguinal Lymph Node Dissection in Penile Cancer: A 4-Year Single-Center Retrospective Study |
|
||||||||||||||
| 4 | 16:27-16:35 |
Application of Bilateral Pedicled Ilioinguinal Flaps for Complete Scrotal Skin Defects after Resection of Malignant Penoscrotal Skin Tumors |
|
||||||||||||||
| 5 | 16:35-16:47 |
Discussion |
|
||||||||||||||
| 1 | 16:47-16:55 |
Role and Mechanisms of the Biomechanical Microenvironment in Regulating Benign Prostatic Hyperplasia |
|
||||||||||||||
| 2 | 16:55-17:03 |
A National Multicenter Prospective Study of the “Verumontanum Occlusion Theory” in Ejaculation-Preserving Blue-Laser Vaporization of the Prostate |
|
||||||||||||||
| 3 | 17:03-17:11 |
Minimally Invasive Treatment and Surgical Approach Selection for Bladder Neck Contracture after Surgery for Benign Prostatic Hyperplasia |
|
||||||||||||||
| 4 | 17:11-17:19 |
Diagnostic and Therapeutic Strategies for Replantation of Complete Penile Amputation: A Report of 25 Cases |
|
||||||||||||||
| 5 | 17:19-17:31 |
Discussion |
|
||||||||||||||
| 1 | 17:31-17:39 |
A Multicenter Randomized Clinical Trial of Letrozole for Impaired Spermatogenesis |
|
||||||||||||||
| 2 | 17:39-17:47 |
Multimodal Biomarker Profiling in Varicocele: Integrated Assessment of Semen Quality, Testicular Elastography, Hormonal and Metabolic Indices Predicts Surgical Recovery |
|
||||||||||||||
| 3 | 17:47-17:55 |
Seminal Plasma PGK2 as a Biomarker for Predicting Improvement in Sperm Motility after Varicocelectomy |
|
||||||||||||||
| 4 | 17:55-18:03 |
Safety, Surgical Outcomes, and Clinical Value of Indocyanine Green Angiographic Fluorescence Imaging in Microscopic Varicocelectomy |
|
||||||||||||||
| 5 | 18:03-18:15 |
Discussion |
|
||||||||||||||
| 1 | 08:00-08:10 |
Opening Remarks |
|
||||||||
| 1 | 08:10-08:20 |
Clinical Value of the Exosomal m6A-F-MDSC Activation Index in Predicting Urosepsis-Associated Acute Kidney Injury |
|
||||||||||||||
| 2 | 08:20-08:30 |
Application of Individualized Fluid Resuscitation in the Management of Postoperative Urosepsis Following Upper Urinary Tract Stone Surgery |
|
||||||||||||||
| 3 | 08:30-08:40 |
Microbial Flora, Drug Resistance Genes and Virulence Factors in Urinary Tract Infection Associated with Infection Stones |
|
||||||||||||||
| 4 | 08:40-08:50 |
- |
|
||||||||||||||
| 5 | 08:50-09:05 |
Discussion |
|
||||||||||||||
| 1 | 09:05-09:15 |
Management of Refractory Fungal Infection After Flexible Ureteroscopic Lithotripsy for Renal Stones |
|
||||||||||||||
| 2 | 09:15-09:25 |
Distribution and Drug Resistance of Pathogens in Urine Cultures from Urological Patients: A Three-Year Single-Center Analysis |
|
||||||||||||||
| 3 | 09:25-09:35 |
A Comparative Analysis of Metabolic and Urinary Bacterial Culture Profiles in Patients with Staghorn versus Non-Staghorn Infectious Renal Stones |
|
||||||||||||||
| 4 | 09:35-09:45 |
Mechanism of Geniposide in Alleviating Calcium Oxalate Stone Formation by Blocking Escherichia coli Fimbria-Renal Tubular Epithelial Receptor Adhesion and Activating the PPARγ Pathway |
|
||||||||||||||
| 5 | 09:45-10:00 |
Discussion |
|
||||||||||||||
| 1 | 10:00-10:10 |
Application of Desmodium styracifolium Total Flavonoid Capsules in Ureteral Stones |
|
||||||||||||||
| 2 | 10:10-10:20 |
Minimally Invasive Treatment Strategies for Upper Urinary Tract Stones Complicated with |
|
||||||||||||||
| 3 | 10:20-10:30 |
Exploration of Percutaneous Nephrolithotomy in the Minimally Invasive Treatment of Retroperitoneal Abscess: A Preliminary Study Based on 6 Clinical Cases |
|
||||||||||||||
| 4 | 10:30-10:40 |
Study on the diagnostic efficacy of the computerized tomography attenuation value of renal pelvis urine in true bacteriuria secondary to renal and ureteral stones |
|
||||||||||||||
| 5 | 10:40-10:55 |
Discussion |
|
||||||||||||||
| 1 | 10:55-11:05 |
From Three-Way Catheter to Modified Bladder Drainage: Outcome Analysis of Delayed Healing in a Case of Complicated Bladder Rupture with Alzheimer's Disease |
|
||||||||||||||
| 2 | 11:05-11:15 |
Research Progress in the Diagnosis and Treatment of Refractory Urinary Tract Infection Associated with Targeted Therapy and Immunotherapy |
|
||||||||||||||
| 3 | 11:15-11:25 |
Occult Fibrinogen Deficiency Diagnosed via Refractory Hematuria After Bilateral Upper Urinary Tract Stone Surgery: A Case Report |
|
||||||||||||||
| 4 | 11:25-11:35 |
Phased Results and Iterative Updates of the Survey Project on the Current Status and Perception of Uncomplicated Urinary Tract Infection Treatment in China |
|
||||||||||||||
| 5 | 11:35-11:50 |
Discussion |
|
||||||||||||||
| 1 | 11:50-12:05 |
Summary |
|
||||||||
| 1 | 13:30-13:40 |
Opening Remarks |
|
|||||
| 2 | 13:40-13:50 |
Discussion |
|
|||||
| 1 | 13:50-14:02 |
Robotic kidney transplantation -- The European experience |
|
||||||||||||||||||||||||||
| 2 | 14:02-14:10 |
Robot-Assisted Single-Port Laparoscopic Transplant Nephrectomy: Preliminary Experience and Technical Considerations (Report of Three Cases) |
|
||||||||||||||||||||||||||
| 3 | 14:10-14:18 |
Robot-Assisted Ureterovesical Reanastomosis for Ureteral Stricture After Kidney Transplantation: Preliminary Experience |
|
||||||||||||||||||||||||||
| 4 | 14:18-14:26 |
Applications of Robot-Assisted Kidney Transplantation in Special Clinical Scenarios and Management of Complex Cases |
|
||||||||||||||||||||||||||
| 5 | 14:26-14:34 |
Feasibility and Safety of Gene-Edited Porcine Red Blood Cells for Normothermic Machine Perfusion of Human Kidneys |
|
||||||||||||||||||||||||||
| 6 | 14:34-14:42 |
Discussion |
|
||||||||||||||||||||||||||
| 1 | 14:42-14:54 |
The Second Pig-to-Human Kidney Xenotransplantation in Asia and a Review of Our Center’s Experience in Kidney Xenotransplantation |
|
|||||||||||||||||||||||||||||
| 2 | 14:54-15:02 |
Eculizumab Combined with Daratumumab for Acute Antibody-Mediated Rejection After Kidney Transplantation: A Single-Center Experience |
|
|||||||||||||||||||||||||||||
| 3 | 15:02-15:10 |
Evaluation of Early Postoperative Outcomes and Prognostic Analysis in Pediatric Kidney Transplantation |
|
|||||||||||||||||||||||||||||
| 4 | 15:10-15:18 |
Early Clinical Experience with Bacteriophage Therapy for Multidrug-Resistant Bacterial Infections in Kidney Transplant Recipients: A Beacon of Hope in the Antimicrobial Resistance Crisis |
|
|||||||||||||||||||||||||||||
| 5 | 15:18-15:26 |
Discussion |
|
|||||||||||||||||||||||||||||
| 1 | 15:26-15:38 |
Renal Cell Carcinoma of the Transplanted Kidney: From Treatment to Origin |
|
||||||||||||||||||||||||||||||||
| 2 | 15:38-15:46 |
Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Nondiabetic Kidney Transplant Recipients |
|
||||||||||||||||||||||||||||||||
| 3 | 15:46-15:54 |
Long-Term Single-Center Follow-Up of the Effects of Denosumab on Mineral and Bone Metabolism in Kidney Transplant Recipients |
|
||||||||||||||||||||||||||||||||
| 4 | 15:54-16:02 |
A prospective study to explore the impact of cardiovascular calcification on the poor prognosis of kidney transplant patients |
|
||||||||||||||||||||||||||||||||
| 5 | 16:02-16:10 |
Discussion |
|
||||||||||||||||||||||||||||||||
| 1 | 16:10-16:22 |
A dynamic model for predicting severe PJP in kidney transplant recipients that integrates machine learning and the timing of infection |
|
|||||||||||||||||||||||||||||
| 2 | 16:22-16:30 |
Multi-Omics and Nanodrug Delivery Study of SPP1 as an Early Predictive Biomarker and Therapeutic Target for Kidney Allograft Fibrosis |
|
|||||||||||||||||||||||||||||
| 3 | 16:30-16:38 |
Mechanisms by Which LRG1 Regulates GPR162/cGAS–STING-Mediated Mitochondrial Dysfunction and Promotes Neutrophil Extracellular Trap Formation in Acute Kidney Injury |
|
|||||||||||||||||||||||||||||
| 4 | 16:38-16:46 |
The Endoplasmic Reticulum Stress–Induced XBP1s–GAS1 Axis Activates Hedgehog Signaling to Promote Tertiary Lymphoid Structure Development After Transplantation of Kidneys from Older Donors |
|
|||||||||||||||||||||||||||||
| 5 | 16:46-16:54 |
Effects of Transitional Care Interventions on Self-Management and Medication Adherence After Discharge in Kidney Transplant Recipients |
|
|||||||||||||||||||||||||||||
| 6 | 16:54-17:02 |
Mechanisms by Which Leucine Metabolism Modulates NK Cell Subset Imbalance to Ameliorate Memory-Like Rejection Following Transplantation |
|
|||||||||||||||||||||||||||||
| 7 | 17:02-17:10 |
Discussion |
|
|||||||||||||||||||||||||||||
| 1 | 17:10-17:20 |
Summary of the Kidney Transplantation Session |
|
|||||
| 1 | 08:00-08:15 |
Opening Remarks |
|
|||||||||||
| 1 | 08:15-08:35 |
Neuro-Urology: What do you need to know? |
|
|||||
| 2 | 08:35-08:43 |
Molecular chronobiology mechanism of sacral neuromodulation for interstitial cystitis: PYCR2/CUL2-MGST3 axis-mediated integrative reprogramming of metabolism–protein homeostasis |
|
|||||
| 3 | 08:43-08:51 |
Comparative study of spinal surgical robot versus 3D-printed template-assisted precise puncture for sacral neuromodulation in tethered cord syndrome |
|
|||||
| 4 | 08:51-08:59 |
Development and application of an intelligent full-cycle bladder function management system for sacral neuromodulation patients |
|
|||||
| 5 | 08:59-09:07 |
Clinical significance of immediate urodynamic study in sacral neuromodulation: a multi-center report of 17 cases |
|
|||||
| 6 | 09:07-09:15 |
Videourodynamic study of bilateral dual-target sacral neuromodulation versus single-target stimulation for complex neurogenic lower urinary tract dysfunction |
|
|||||
| 7 | 09:15-09:23 |
Development of a standardized clinical pathway for sacral neuromodulation (SNM) and initial experience |
|
|||||
| 8 | 09:23-09:31 |
Factors influencing adherence to clean intermittent catheterization in neurogenic bladder patients and the development and application of an optimized nursing intervention program |
|
|||||
| 9 | 09:31-09:39 |
Effect and mechanism of optogenetic modulation of lumbosacral motor neurons on detrusor–sphincter dyssynergia in rats with spinal cord injury |
|
|||||
| 10 | 09:39-09:47 |
Multidimensional neuro-electroacupuncture regulation for voiding dysfunction after iatrogenic pelvic floor nerve injury: a real-world observation |
|
|||||
| 11 | 09:47-10:02 |
Discussion |
||||||
| 1 | 10:02-10:22 |
Is Prostatectomy an Effective Therapeutic Option for Men with Detrusor Underactivity caused by Chronic Prostatic BOO? |
|
|||||
| 2 | 10:22-10:42 |
Ejaculatory dysfunction following surgery for benign prostatic obstruction - a real or industry manufactured concern? |
|
|||||
| 3 | 10:42-10:50 |
Clinical study of medial umbilical ligament sling-reinforced complete anatomical reconstruction to improve urinary continence after robotic radical prostatectomy |
|
|||||
| 4 | 10:50-10:58 |
Treatment options for stress urinary incontinence after radical prostatectomy |
|
|||||
| 5 | 10:58-11:06 |
Digital twin-based dynamic assessment and regional graded management of LUTS in middle-aged and older men based on multi-source data fusion |
|
|||||
| 6 | 11:06-11:14 |
Standardized technique and clinical outcomes of super-pulsed thulium laser enucleation of the prostate: a propensity score-matched real-world study |
|
|||||
| 7 | 11:14-11:22 |
1-monopalmitin ameliorates benign prostatic hyperplasia by inhibiting endoplasmic reticulum stress and androgen receptor signaling |
|
|||||
| 8 | 11:22-11:30 |
Targeted therapy for prostatic fibrosis based on tetrahedral framework nucleic acid delivery of PDLIM4/YAP1 blocking peptides |
|
|||||
| 9 | 11:30-11:38 |
Perioperative management and efficacy evaluation of water vapor thermal therapy for elderly high-risk patients with benign prostatic hyperplasia |
|
|||||
| 10 | 11:38-11:46 |
Prospective randomized controlled trial of transurethral robotic waterjet prostate resection for benign prostatic hyperplasia |
|
|||||
| 11 | 11:46-11:54 |
Literature review and experience sharing of local anesthesia surgery for benign prostatic hyperplasia |
|
|||||
| 12 | 11:54-12:10 |
Discussion |
||||||
| 1 | 13:15-13:30 |
Clinical applications of Smooth mode Er:YAG laser in mild to moderate female stress urinary incontinence |
|
|||||
| 1 | 13:30-13:50 |
Robotic Artificial Urinary Sphincter Implantation in Women Using the EDGE MP1000 Robot: The First Worldwide Experience |
|
|||||
| 2 | 13:50-13:58 |
Long-term efficacy of tension-free vaginal tape (TVT) for patients with stress urinary incontinence complicated by detrusor underactivity |
|
|||||
| 3 | 13:58-14:06 |
Efficacy of mesh-free laparoscopic native tissue reconstruction based on the integral theory of the pelvic floor for advanced pelvic organ prolapse with stress urinary incontinence |
|
|||||
| 4 | 14:06-14:14 |
Efficacy and safety of transvaginal mesh-augmented posterior pelvic reconstruction for patients with severe rectocele or posterior vaginal wall prolapse |
|
|||||
| 5 | 14:14-14:22 |
The law of elastic collision refutes the hammock theory: revisiting the mechanical mechanism of female stress urinary incontinence |
|
|||||
| 6 | 14:22-14:30 |
A randomized, single-blind, placebo-controlled clinical trial of low-intensity pulsed ultrasound (LIPUS) therapy for female stress urinary incontinence (SUI) |
|
|||||
| 7 | 14:30-14:38 |
Clinical efficacy of electroacupuncture combined with pelvic floor muscle training for post-prostatectomy stress urinary incontinence: a randomized controlled trial |
|
|||||
| 8 | 14:38-14:46 |
Robot-assisted four-arm urethral sling combined with intraoperative urodynamic feedback for complex stress urinary incontinence after epispadias surgery |
|
|||||
| 9 | 14:46-14:54 |
Association of male urgency urinary incontinence and nocturia with the disease burden of benign prostatic hyperplasia: a cross-database national analysis of developed countries |
|
|||||
| 10 | 14:54-15:04 |
Discussion |
||||||
| 1 | 15:04-15:12 |
Investigating the role and mechanism of ASC-derived extracellular vesicle perfusion enriched with miR-199a-3p in detrusor underactivity using a bladder microfluidic chip |
|
|||||
| 2 | 15:12-15:20 |
A spiky nanoparticle–thermosensitive hydrogel composite system for intravesical delivery of botulinum toxin type A and treatment of overactive bladder |
|
|||||
| 3 | 15:20-15:28 |
Role and mechanism of Piezo1-mediated mechanogated ion channels in the bladder urothelium in the initiation of the micturition reflex |
|
|||||
| 4 | 15:28-15:36 |
Nanocomplex-mediated delivery of siRNA targeting TLR3 restores urothelial integrity and alleviates interstitial cystitis |
|
|||||
| 5 | 15:36-15:44 |
Clinical value of a voiding diary combined with post-void residual volume measurement in diagnosing small-volume benign prostatic hyperplasia with interstitial cystitis/bladder pain syndrome in primary hospitals |
|
|||||
| 6 | 15:44-15:52 |
Role and mechanism of PIEZO1-mediated mechanosensitive signaling in bladder hypersensitivity in interstitial cystitis/bladder pain syndrome |
|
|||||
| 7 | 15:52-16:02 |
Basic and translational study of human umbilical cord mesenchymal stem cell exosomes delivered via thermosensitive hydrogel for radiation cystitis |
|
|||||
| 1 | 16:02-16:10 |
Application of the modified York–Mason procedure in the repair of urethrorectal fistula after radical prostatectomy |
|
|||||
| 2 | 16:10-16:18 |
Diagnostic accuracy of large language models in the automated interpretation of urodynamic parameters: a comparative study with urologists of varying experience |
|
|||||
| 3 | 16:18-16:26 |
Simultaneous electroencephalography–urodynamic study to assess cortical electrophysiological features of lower urinary tract dysfunction |
|
|||||
| 4 | 16:26-16:34 |
Development and validation of an integrated portable uroflowmetry device |
|
|||||
| 5 | 16:34-16:42 |
Construction of a machine learning model for predicting stage I conversion of sacral neuromodulation for neurogenic bladder |
|
|||||
| 6 | 16:42-16:50 |
Clinical study on the efficacy and safety of digital therapeutics for overactive bladder |
|
|||||
| 7 | 16:50-16:58 |
Clinical efficacy of increasing urethral circumference combined with artificial urinary sphincter implantation for incontinence after anastomotic urethroplasty for traumatic urethral stricture |
|
|||||
| 8 | 16:58-17:06 |
Application of enterocystoplasty in children with low-compliance bladder |
|
|||||
| 9 | 17:06-17:16 |
Discussion |
||||||
| 1 | 08:00-08:10 |
Opening Remarks |
|
|||||
| 1 | 08:10-08:20 |
Where Robotic Surgery Entered the Urologic Operating Room: Beginnings of a Surgical Revolution |
|
|||||||||||||||||
| 2 | 08:20-08:30 |
Techniques for nerve-sparing robotic radical prostatectomy |
|
|||||||||||||||||
| 3 | 08:30-08:40 |
Safety and Efficacy of Robot-Assisted Radical Prostatectomy Using a Chinese-Developed Single-Port Robotic System: A Prospective Single-Arm Study and Propensity Score-Matched Comparative Analysis |
|
|||||||||||||||||
| 4 | 08:40-08:50 |
Clinical Outcomes of the Extraperitoneal C.R.P.C. Four-Step Technique Versus Conventional Laparoscopic Radical Prostatectomy |
|
|||||||||||||||||
| 5 | 08:50-09:00 |
Robot-Assisted Single-Port Extraperitoneal Radical Prostatectomy with Full-Length Urethral Preservation |
|
|||||||||||||||||
| 6 | 09:00-09:10 |
The Lisbon Zero clip RARP: improving outcome |
|
|||||||||||||||||
| 7 | 09:10-09:20 |
Discussion |
|
|||||||||||||||||
| 1 | 09:20-09:30 |
Application of Tension-Free Vesicourethral Anastomosis in Single-Port Transvesical Robot-Assisted Radical Prostatectomy |
|
||||||||||||||
| 2 | 09:30-09:40 |
Integrated Reconstruction and Suspension Technique for Improving Early Urinary Continence after Robot-Assisted Radical Prostatectomy: A Prospective Multicenter Clinical Study |
|
||||||||||||||
| 3 | 09:40-09:50 |
Application of the Three-Arm RNRS-RARP Technique |
|
||||||||||||||
| 4 | 09:50-10:00 |
A Novel Urethral Reconstruction Technique Versus Standard Vesicourethral Anastomosis in Robot-Assisted Radical Prostatectomy: A Retrospective Cohort Study |
|
||||||||||||||
| 5 | 10:00-10:10 |
Preliminary Outcomes of Salvage Robot-Assisted Radical Prostatectomy for Recurrent Prostate Cancer after High-Frequency Irreversible Electroporation (H-FIRE) |
|
||||||||||||||
| 6 | 10:10-10:20 |
Clinical Outcomes of Urethral Structure Preservation in Robot-Assisted Radical Prostatectomy |
|
||||||||||||||
| 7 | 10:20-10:30 |
Discussion |
|
||||||||||||||
| 1 | 10:30-10:40 |
An Interpretable Machine Learning Model Based on Multidimensional Feature Fusion for Predicting Urinary Continence Recovery after Robot-Assisted Radical Prostatectomy: A Dual-Center Retrospective Cohort Study |
|
||||||||||||||
| 2 | 10:40-10:50 |
A Phase II Clinical Study of the Safety and Efficacy of the PSMA-Targeted Fluorescent Imaging Agent DGPR1008 for Intraoperative Imaging during Robot-Assisted Radical Prostatectomy |
|
||||||||||||||
| 3 | 10:50-11:00 |
Real-Time Deep Learning Prediction of the Optimal Apical Transection Line during Robot-Assisted Radical Prostatectomy: Development, Multidimensional Evaluation, and Multicenter Validation |
|
||||||||||||||
| 4 | 11:00-11:10 |
Potential Applications of Fluorescence Microscopy Combined with PSMA Probes and AI-Assisted Interpretation for Surgical Margin Assessment in RARP |
|
||||||||||||||
| 5 | 11:10-11:20 |
Deformable Mixed-Reality Navigation Based on Nonrigid Registration for Robot-Assisted Radical Prostatectomy in High-Risk Prostate Cancer: A Prospective Randomized Controlled Trial |
|
||||||||||||||
| 6 | 11:20-11:30 |
Discussion |
|
||||||||||||||
| 1 | 11:30-11:40 |
Is an Open Radical Cystectomy in the Era of Robotics Still Allowed? |
|
||||||||||||||
| 2 | 11:40-11:50 |
A Direct Prediction System for Sequential Transection Boundaries and Safety Windows during Bladder Neck Transection in Robot-Assisted Radical Prostatectomy: A Multi-Reader, Multi-Case (MRMC) Study and Prospective Silent-Deployment Study |
|
||||||||||||||
| 3 | 11:50-12:00 |
Comparison of Oncological Outcomes between Anterior- and Posterior-Approach Robotic Surgery for Locally Advanced Prostate Cancer: A Single-Center Study of 331 Patients |
|
||||||||||||||
| 4 | 12:00-12:10 |
Application of Photon-Counting CT–Based Prostatic Artery Reconstruction to Guide Prostatic Artery Pre-occlusion for Neurovascular Bundle Preservation during Robot-Assisted Laparoscopic Radical Prostatectomy |
|
||||||||||||||
| 5 | 12:10-12:20 |
Combined Anterior and Posterior Robotic Approaches (Bocciardi + Hood Techniques) for Radical Prostatectomy in Patients with Large-Volume Prostates |
|
||||||||||||||
| 6 | 12:20-12:30 |
Discussion |
|
||||||||||||||
| 1 | 13:05-13:20 |
Applications of Robot-Assisted Surgery in Upper Urinary Tract Diseases |
|
|||||
| 1 | 13:20-13:30 |
Evolution and Innovation of Transvesical Robot-Assisted Radical Prostatectomy: From Multi-Arm to Single-Arm Single-Port Techniques |
|
|||||||||||||||||
| 2 | 13:30-13:40 |
How to Establish a Successful Robotic Service |
|
|||||||||||||||||
| 3 | 13:40-13:50 |
From Learning Curve to Global Standard: Training and Proctoring Models in Robotic Urology |
|
|||||||||||||||||
| 4 | 13:50-14:00 |
Robotic Prostate Enucleation |
|
|||||||||||||||||
| 5 | 14:00-14:10 |
Single-Port Transvesical Robot-Assisted Prostate Enucleation for Large-Volume Prostates (>200 mL) |
|
|||||||||||||||||
| 6 | 14:10-14:20 |
Feasibility and Safety of Single-Port Robot-Assisted Radical Prostatectomy Using the EDGE SP1000 System: A Single-Center Early Experience |
|
|||||||||||||||||
| 7 | 14:20-14:30 |
Development of an Ex Vivo Porcine Kidney Model of Complex Renal Tumors and Its Preliminary Application in Simulation Training for Robot-Assisted Partial Nephrectomy |
|
|||||||||||||||||
| 8 | 14:30-14:40 |
Discussion |
|
|||||||||||||||||
| 1 | 14:40-14:50 |
Off-clamp robotic multiport/SP partial nephrectomy: a journey through the complexity of renal masses |
|
||||||||||||||
| 2 | 14:50-15:00 |
Systematic Perioperative Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus: A Single-Center Multidisciplinary Integrated Practice |
|
||||||||||||||
| 3 | 15:00-15:10 |
Propensity Score-Matched Analysis of Lateral versus Prone Retroperitoneal Robot-Assisted Partial Nephrectomy |
|
||||||||||||||
| 4 | 15:10-15:20 |
Clinical Characteristics and Treatment Outcomes of Urinary Leakage after Robot-Assisted Partial Nephrectomy |
|
||||||||||||||
| 5 | 15:20-15:30 |
Development of a Visualized Resection Planning System for Robot-Assisted Partial Nephrectomy of Completely and Highly Endophytic Renal Tumors: A Prospective Clinical Study |
|
||||||||||||||
| 6 | 15:30-15:40 |
Renal Core Temperature Distribution and Associated Factors during Ice-Slush Cooling in Robot-Assisted Partial Nephrectomy: A Technical Report from a Prospective Randomized Controlled Study |
|
||||||||||||||
| 7 | 15:40-15:50 |
Discussion |
|
||||||||||||||
| 1 | 15:40-16:00 |
Surgical Techniques and Experience with Totally Robot-Assisted Radical Cystectomy and Ileal Conduit Urinary Diversion in Women |
|
||||||||||||||
| 2 | 16:00-16:10 |
Evolution of Surgical Strategies and Safety Assessment for Renal Cell Carcinoma with Mayo Level IV Venous Tumor Thrombus in the Robotic Era |
|
||||||||||||||
| 3 | 16:10-16:20 |
Robot-Assisted Ileal Ureter Substitution for Ureteral Avulsion: Surgical Technique and Clinical Outcomes |
|
||||||||||||||
| 4 | 16:20-16:30 |
Robot-Assisted Vena Cava Resection versus Thrombectomy for Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus: A Case-Control Study of Indications and Outcomes |
|
||||||||||||||
| 5 | 16:30-16:40 |
Robot-Assisted Laparoscopic Management of Complex Complications after Orthotopic Ileal Neobladder Reconstruction: Exploration and Practice |
|
||||||||||||||
| 6 | 16:40-16:50 |
Discussion |
|
||||||||||||||
| 1 | 16:50-17:00 |
Preliminary Experience with Robot-Assisted Laparoscopic Surgery for Lower Urinary Tract Reconstruction: Experience from a Urinary Tract Reconstruction Center |
|
||||||||||||||
| 2 | 17:00-17:10 |
Preliminary Experience with Totally Intracorporeal Bilateral Ileal Ureter Substitution Using the Chinese-Developed KangDuo 2.0 Robotic System |
|
||||||||||||||
| 3 | 17:10-17:20 |
Technical Evolution of Robot-Assisted Left Renal Vein Transposition for Nutcracker Syndrome and Precision Treatment Strategies Based on Anatomical Classification |
|
||||||||||||||
| 4 | 17:20-17:30 |
Preliminary Clinical Experience with Robot-Assisted Transanal Repair of Rectovesical Fistula after Radical Prostatectomy |
|
||||||||||||||
| 5 | 17:30-17:40 |
Comparison of Suprapubic Catheterization versus Urethral Catheterization after Extraperitoneal Single-Port Robot-Assisted Radical Prostatectomy |
|
||||||||||||||
| 6 | 17:40-17:50 |
Discussion |
|
||||||||||||||
| 1 | 17:50-17:55 |
Summary |
|
|||||
| 1 | 08:00-08:10 |
Opening Remarks |
|
|||||
| 1 | 08:10-08:18 |
Development of a comprehensive MRI-based difficulty scoring system for prostate enucleation and its predictive value for surgical efficiency and safety |
|
|||||||||||||||||||||||||||||||||||
| 2 | 08:18-08:26 |
Predictive factors of stress urinary incontinence after Holmium Laser Enucleation of the Prostate: a magnetic resonance imaging-based retrospective study |
|
|||||||||||||||||||||||||||||||||||
| 3 | 08:26-08:34 |
AEEP: the Anatomic Endoscopic Enucleation of the Prostate: a step forward to redefine the gold standard in BPH therapy |
|
|||||||||||||||||||||||||||||||||||
| 4 | 08:34-08:42 |
Efficacy of thulium laser enucleation of the prostate with preservation of a longitudinal strip of urethral mucosa at the 12 o'clock position for benign prostatic hyperplasia with small- to medium-sized prostates |
|
|||||||||||||||||||||||||||||||||||
| 5 | 08:42-08:50 |
Comparison of the efficacy and safety of transurethral blue laser versus holmium laser enucleation of the prostate for benign prostatic hyperplasia |
|
|||||||||||||||||||||||||||||||||||
| 6 | 08:50-08:58 |
Feasibility of Simultaneous Transperineal Prostate Biopsy and ThuLEP in Patients with Bladder Outlet Obstruction, Gray-Zone PSA, and PI-RADS 3 Lesions |
|
|||||||||||||||||||||||||||||||||||
| 7 | 08:58-09:06 |
AI-based image recognition for identifying bleeding sites during transurethral laser enucleation of the prostate and evaluation of the effects of Qianliean suppositories |
|
|||||||||||||||||||||||||||||||||||
| 8 | 09:06-09:16 |
Discussion |
|
|||||||||||||||||||||||||||||||||||
| 1 | 09:16-09:24 |
Efficacy of ureteroscopic holmium laser lithotripsy in situ versus after stone relocation for proximal ureteral stones |
|
||||||||||||||||||||||||||||||||
| 2 | 09:24-09:32 |
New modalities to improve safety during TFL lithotripsy |
|
||||||||||||||||||||||||||||||||
| 3 | 09:32-09:40 |
Thulium fiber laser versus holmium: YAG laser for ureteroscopic lithotripsy of ureteral stones: a systematic review and meta-analysis |
|
||||||||||||||||||||||||||||||||
| 4 | 09:40-09:48 |
Clinical efficacy and safety of combined thulium and holmium lasers for calyceal diverticular stones |
|
||||||||||||||||||||||||||||||||
| 5 | 09:48-09:56 |
Ureteral stricture after rigid ureteroscopic laser lithotripsy: Which matters more, stone impaction or laser injury? |
|
||||||||||||||||||||||||||||||||
| 6 | 09:56-10:04 |
Flexible ureteroscopic laser lithotripsy with continued antithrombotic therapy: A multicenter real-world study |
|
||||||||||||||||||||||||||||||||
| 7 | 10:04-10:12 |
High-frequency, low-energy versus low-frequency, high-energy holmium laser lithotripsy during flexible ureteroscopy with a flexible-tip suction access sheath: A comparison of efficacy |
|
||||||||||||||||||||||||||||||||
| 8 | 10:12-10:22 |
Discussion |
|
||||||||||||||||||||||||||||||||
| 1 | 10:22-10:30 |
Superpulsed thulium laser biopsy of renal pelvic tumors: Clinical experience in 20 cases |
|
||||||||||||||||||||||||||||||||
| 2 | 10:30-10:38 |
Super-inert near-infrared fluorescent dyes for high-contrast intraoperative navigation imaging: Insights from a Nature Photonics study |
|
||||||||||||||||||||||||||||||||
| 3 | 10:38-10:46 |
Laser applications in the treatment of renal tumors: Current use and research advances |
|
||||||||||||||||||||||||||||||||
| 4 | 10:46-10:54 |
High-power side-firing green laser-assisted off-clamp laparoscopic partial nephrectomy for T1a renal tumors: Initial clinical experience |
|
||||||||||||||||||||||||||||||||
| 5 | 10:54-11:02 |
Transurethral anatomical resection of intramural ureteral tumors using a 12.5 W thulium laser: A 2-year follow-up report |
|
||||||||||||||||||||||||||||||||
| 6 | 11:02-11:10 |
Thulium laser ablation for primary bladder neck obstruction in men: Preliminary evaluation of efficacy |
|
||||||||||||||||||||||||||||||||
| 7 | 11:10-11:18 |
Applications of thulium lasers in upper urinary tract diseases |
|
||||||||||||||||||||||||||||||||
| 8 | 11:18-11:28 |
Discussion |
|
||||||||||||||||||||||||||||||||
| 1 | 11:28-11:35 |
En bloc laser enucleation of the prostate |
|
||||||||||||||||||||
| 2 | 11:35-11:42 |
Use of a flexible and navigable suction ureteral access sheath (FANS) for renal stones with purulent debris in the renal pelvis |
|
||||||||||||||||||||
| 3 | 11:42-11:49 |
Application of thulium laser in en bloc enucleation of non-muscle-invasive bladder tumors |
|
||||||||||||||||||||
| 4 | 11:49-11:55 |
Discussion |
|
||||||||||||||||||||
| 1 | 13:30-13:35 |
Opening Remarks |
|
||||||||||||||||||||||||||||||||
| 2 | 13:35-13:40 |
Opening Remarks |
|
||||||||||||||||||||||||||||||||
| 3 | 13:40-13:45 |
Chinese Expert Consensus on Whole-course Management of Prostate Cancer in Grassroots Settings |
|
||||||||||||||||||||||||||||||||
| 4 | 13:45-13:55 |
Chinese Expert Consensus on Whole-course Management of Prostate Cancer in Primary Care Interpretation |
|
||||||||||||||||||||||||||||||||
| 1 | 13:55-14:05 |
Clinical Efficacy of Vacuum Sealing Drainage (VSD) in Scrotal Gangrene and Its Comparison with Conventional Therapy |
|
|||||||||||||||||
| 2 | 14:05-14:20 |
Bridging Continents: How Chinese-Trained Doctors and Made-in-China Devices are Transforming Urological Care in Africa --- Lessons from Somalia |
|
|||||||||||||||||
| 3 | 14:20-14:35 |
Building a robotic urology program in Morocco: from inception to more than 1,000 procedures |
|
|||||||||||||||||
| 4 | 14:35-14:55 |
Discussion |
|
|||||||||||||||||
| 1 | 14:55-15:05 |
Preliminary Study on the Application of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Renal Tumors |
|
|||||||||||||||||
| 2 | 15:05-15:15 |
Application of Antegrade Flexible Ureteroscopy via Percutaneous Nephrostomy Tract in Special Ureteral Calculi |
|
|||||||||||||||||
| 3 | 15:15-15:30 |
Cross-regional Robotic Surgery: Lessons from Toumai Cooperation Projects |
|
|||||||||||||||||
| 4 | 15:30-15:40 |
Study on Digital Pathology and Immunohistochemistry-Assisted Scoring Technology of Renal Cell Carcinoma for Grassroots Application |
|
|||||||||||||||||
| 5 | 15:50-16:00 |
Discussion |
|
|||||||||||||||||
| 1 | 16:00-16:10 |
Morphological Classification of Dorsal Venous Complex on MRI, Correlation Analysis of Blood Flow Parameters and Construction of Preoperative Individualized Evaluation Model for Radical Prostatectomy |
|
||||||||||||||
| 2 | 16:10-16:20 |
An Artificial Intelligence Uroflowmetry System Based on Smartphone Video and Deep Learning Liquid Level Recognition: Prospective Clinical and Bench Validation |
|
||||||||||||||
| 3 | 16:20-16:30 |
Research and Development of Key Technologies, Platform Construction and Application of Artificial Intelligence-Based Precision Diagnosis and Treatment for Renal Cell Carcinoma |
|
||||||||||||||
| 4 | 16:30-16:40 |
Comprehensive Therapy for Oligometastatic Urothelial Carcinoma |
|
||||||||||||||
| 5 | 16:40-17:00 |
Discussion |
|
||||||||||||||
| 1 | 17:00-17:10 |
Surgical Selection and Therapeutic Outcomes of Posterior Urethral Rupture or Atresia Secondary to Pelvic Fracture |
|
||||||||||||||
| 2 | 17:10-17:20 |
Construction and Clinical Practice Exploration of Community Urological Health Service System Under the National Strengthening Foundation Policy |
|
||||||||||||||
| 3 | 17:20-17:30 |
Management of Intraoperative Intestinal and Ureteral Complications During Laparoscopic Radical Cystectomy for Bladder Cancer |
|
||||||||||||||
| 4 | 17:30-17:50 |
Discussion |
|
||||||||||||||
| 1 | 08:00-08:10 |
Opening Remarks |
|
|||||
| 1 | 08:10-08:18 |
Preliminary Study on the Efficacy and Safety of Non-ischemic Partial Nephrectomy for Renal Tumors |
|
|||||
| 2 | 08:18-08:26 |
Application of Frozen Section-Assisted Nerve Preservation in Robotic Surgery for Locally Advanced Prostate Cancer |
|
|||||
| 3 | 08:26-08:34 |
Contemporary Surgical Strategies in Robotic Partial Nephrectomy |
|
|||||
| 4 | 08:34-08:42 |
The "SLICE" Technique Improves Renal Function and Oncological Outcomes in Patients with Intermediate- and High-Complexity Scores Undergoing Robotic Partial Nephrectomy |
|
|||||
| 5 | 08:42-08:50 |
Robot-Assisted Laparoscopic Partial Nephrectomy via the Retroperitoneal Approach in the Prone Position: Exploration and Application of a Novel Position (Report of 160 Cases) |
|
|||||
| 6 | 08:50-08:58 |
Comparison of Clinical Efficacy Between Robotic and Open Surgery for Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus: A 15-Year Single-Center Experience with Propensity Score Matching Analysis |
|
|||||
| 7 | 08:58-09:10 |
Discussion |
||||||
| 1 | 09:10-09:18 |
Single-Center Experience of Nerve-Sparing Technique in Robot-Assisted Single-Port Radical Prostatectomy |
|
|||||
| 2 | 09:18-09:26 |
Robot-Assisted Radical Cystectomy with Prostate Preservation and Orthotopic Ileal Neobladder: A Preliminary Exploration (Report of 13 Cases) |
|
|||||
| 3 | 09:26-09:34 |
A New Option for Urethral Reconstruction in the Robotic Era: Clinical Practice of Robot-Assisted Laparoscopic Retropubic Approach for Urethral Defects Following Pelvic Fracture |
|
|||||
| 4 | 09:34-09:42 |
Bladder–Prostate Suspension (Detrusor–Prostate Suspension) for Early Continence Recovery After Robot-Assisted Radical Prostatectomy: A Preliminary Experience |
|
|||||
| 5 | 09:42-09:50 |
Effect of Membrane Anatomy–Based Complete Intrafascial Dissection with Clamp-Free and Suture-Free Technique on Continence and Sexual Function After Robot-Assisted Radical Prostatectomy for Prostate Cancer |
|
|||||
| 6 | 09:50-09:58 |
Does Robot-Assisted Partial Nephrectomy Reduce the Risk of Clinically Significant Bleeding? |
|
|||||
| 7 | 09:58-10:10 |
Discussion |
||||||
| 1 | 10:10-10:18 |
Clinical Experience of 70 Cases of Transperineal Single-Port Robot-Assisted Radical Prostatectomy |
|
|||||
| 2 | 10:18-10:26 |
Multimodal Radiomics–Guided Individualized Surgical Strategy for Single-Port Robot-Assisted Laparoscopic Radical Prostatectomy (RALP) |
|
|||||
| 3 | 10:26-10:34 |
Robot-Assisted Transvaginal Hybrid NOTES Nephrectomy: Clinical Experience in 23 Cases |
|
|||||
| 4 | 10:34-10:42 |
Clinical Application and Preliminary Evaluation of Single-Port Surgical Robotic System in Urological Surgery |
|
|||||
| 5 | 10:42-10:50 |
Feasibility, Safety, and Efficacy of a Single-Port Robotic Surgical Platform for Robot-Assisted Laparoscopic Pyeloplasty in Children: A Preliminary Study |
|
|||||
| 6 | 10:50-11:00 |
Discussion |
||||||
| 1 | 11:00-11:08 |
Complexity Under Control: The Art of Advanced Laparoscopic Partial Nephrectomy |
|
|||||
| 2 | 11:08-11:16 |
Is There Still a Role for Laparoscopy in Renal Surgery? Between Competition and Complementarity in the Robotic Era |
|
|||||
| 3 | 11:16-11:24 |
Application of Modified Partial Cystectomy Combining Laparoscopy and Cystoscopy in Bladder-Preserving Treatment |
|
|||||
| 4 | 11:24-11:32 |
Extraperitoneal Approach for Fertility-Preserving Totally Laparoscopic Radical Cystectomy with Orthotopic Ileal Neobladder |
|
|||||
| 5 | 11:32-11:40 |
Long-Term Changes in Renal Parenchymal Volume and Estimated Glomerular Filtration Rate After Minimally Invasive Partial Nephrectomy for Renal Cell Carcinoma: A Study with a Median Follow-Up of 47.4 Months |
|
|||||
| 6 | 11:40-11:50 |
Discussion |
||||||
| 1 | 11:50-11:58 |
The Posterior Route: Rethinking Laparoscopic Adrenalectomy |
|
|||||
| 2 | 11:58-12:06 |
Preclinical Feasibility Study of Pure Laparoscopic Posterior Approach Radical Prostatectomy in a Porcine Model (with Video Presentation) |
|
|||||
| 3 | 12:06-12:14 |
Single-Center Evaluation of Oncological Efficacy and Safety of Laparoscopic Partial Cystectomy Using a No-Touch Technique |
|
|||||
| 4 | 12:14-12:22 |
Application of a Standardized Envelope Excision Technique in Laparoscopic Radical Cystectomy: A Multicenter Report |
|
|||||
| 5 | 12:22-12:30 |
Discussion |
||||||
| 1 | 12:30-12:38 |
Changing Treatment Strategies in UTUC |
|
|||||
| 2 | 12:38-12:46 |
Minimally Invasive Treatment of Postoperative Urinary Tract Obliteration After Upper Urinary Tract Stone Surgery |
|
|||||
| 3 | 12:46-12:54 |
Endoscopic Ablation Combined with Systemic Comprehensive Therapy for Kidney-Preserving Treatment of Localized High-Risk Upper Tract Urothelial Carcinoma: A Series of Clinical Studies from West China Hospital |
|
|||||
| 4 | 12:54-13:02 |
Role and Significance of Urinary Tract Infection in Percutaneous Nephrolithotomy (PCNL): A Prospective Multicenter Study |
|
|||||
| 5 | 13:02-13:10 |
Efficacy Analysis of Endoscopic Kidney-Preserving Surgery for High-Risk Upper Tract Urothelial Carcinoma |
|
|||||
| 6 | 13:10-13:18 |
Preliminary Experience with Flexible Ureteroscopy Combined with Percutaneous Renal Puncture Localization for Recurrent Parapelvic Cysts in the Oblique Supine Position: A Report of 4 Cases |
|
|||||
| 7 | 13:18-13:26 |
Comparison of the Efficacy of Contrast-Enhanced Ultrasound-Guided versus Conventional Ultrasound-Guided Percutaneous Nephrolithotomy for Renal Stones: A Retrospective Cohort Study |
|
|||||
| 8 | 13:26-13:40 |
Discussion |
||||||
| 1 | 13:40-13:48 |
Risk Stratification and Image-Guided Practice in Robot-Assisted Partial Nephrectomy for Complex Renal Tumors |
|
|||||
| 2 | 13:48-13:56 |
Fusion magnetic navigation in focal therapy of prostate cancer |
|
|||||
| 3 | 13:56-14:04 |
Multicenter Clinical Study of a Percutaneous Nephrolithotomy Puncture Navigation System Based on Stereoscopic Vision Localization Technology |
|
|||||
| 4 | 14:04-14:12 |
Artificial Intelligence–Driven Three-Dimensional Reconstruction and Surgical Planning for Optimizing "Fan-Shaped Pre-Suturing Clampless Resection" in the Treatment of Renal Tumors |
|
|||||
| 5 | 14:12-14:20 |
Comparison of Transperineal mpMRI–Ultrasound Image Fusion and Transrectal Cognitive Fusion Prostate Biopsy |
|
|||||
| 6 | 14:20-14:28 |
Indocyanine Green Fluorescence in Pelvic Lymph Node Dissection: A Randomized Controlled Trial |
|
|||||
| 7 | 14:28-14:40 |
Discussion |
||||||
| 1 | 14:40-14:48 |
A Prospective Randomized Controlled Trial of Transurethral Plasma Kinetic Enucleation with Preemptive Apical Dissection versus Conventional Prostate Enucleation |
|
|||||
| 2 | 14:48-14:56 |
Aquablation for BPH and Prostate Cancer: Current Status |
|
|||||
| 3 | 14:56-15:04 |
Domestic Plough-Shaped Electrode Transurethral Enucleation of the Prostate: Learning Curve Breakthrough and Efficacy Evaluation Based on "Face-to-Face Contact" Mechanical Reconstruction |
|
|||||
| 4 | 15:04-15:12 |
Safety and Efficacy of the Implantable Prostate Suspension System (Urowell) for the Treatment of Benign Prostatic Hyperplasia: A Prospective, Multicenter, Randomized Controlled, Non-Inferiority Clinical Trial |
|
|||||
| 5 | 15:12-15:20 |
Single-Center Experience with Transurethral Vaporization Enucleation of the Prostate Using a Plough-Shaped Electrode for Benign Prostatic Hyperplasia (152 Cases) |
|
|||||
| 6 | 15:20-15:28 |
Preliminary Observation of En Bloc Resection with the β Knife Combined with Bladder Neck Incision for Non-Muscle-Invasive Bladder Cancer with Bladder Outlet Obstruction |
|
|||||
| 7 | 15:28-15:40 |
Discussion |
||||||
| 1 | 15:40-15:48 |
Tumor Rupture During Partial Nephrectomy |
|
|||||
| 2 | 15:48-15:56 |
Transperineal focal ablation for localized prostate cancer: from fusion-guided biopsy to laser and microwave therapies |
|
|||||
| 3 | 15:56-16:04 |
Preliminary Summary of 1,000-Case Experience with Transurethral Water Vapor Thermal Therapy for the Prostate at Nanjing Drum Tower Hospital |
|
|||||
| 4 | 16:04-16:12 |
Efficacy and Safety of Transurethral Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia: Evidence from a Prospective Multicenter Randomized Controlled Trial |
|
|||||
| 5 | 16:12-16:20 |
Comparison of Sexual Function, Urinary Continence, and Early Oncological Outcomes After Radical Prostatectomy versus Irreversible Electroporation in Patients with Localized Prostate Cancer: A Single-Center Retrospective Cohort Study and Inverse Probability of Treatment Weighting Analysis |
|
|||||
| 6 | 16:20-16:28 |
Efficacy and Safety Analysis of Peritoneal Coverage and Fixation After Transabdominal Radical Prostatectomy |
|
|||||
| 7 | 16:28-16:36 |
Etiology Analysis and Management of Subcapsular Renal Hematoma After Ureteroscopy |
|
|||||
| 8 | 16:36-16:44 |
Clinical Application of the Retrograde Double-Row Needle Placement Technique in Water Vapor Thermal Therapy for Large-Volume (>50 mL) Benign Prostatic Hyperplasia |
|
|||||
| 9 | 16:44-16:56 |
Discussion |
||||||
| 1 | 16:56-17:00 |
Summary |
|
|||||
| 1 | 08:00-08:10 |
Opening Remarks |
|
||||||||
| 1 | 08:20-08:30 |
Genetics in prostate cancer: from hereditary risk to precision medicine |
|
|||||
| 2 | 08:30-08:40 |
All Roads Lead to AR: The Androgen Receptor in Modern Prostate Cancer Care |
|
|||||
| 3 | 08:40-08:50 |
Immunosuppressive and Prognostic Significance of MS4A4A-Positive Macrophages in Bladder Cancer |
|
|||||
| 4 | 08:50-09:00 |
Single-Cell and Spatial Transcriptomics Reveal Metastatic Subtyping and Molecular Mechanisms of Pheochromocytoma |
|
|||||
| 5 | 09:00-09:10 |
The VGF-MYH9-GSK3β-Wnt/β-Catenin Axis Promotes Prostate Cancer Progression by Reprogramming Glycolysis and the Immune Microenvironment |
|
|||||
| 6 | 09:10-09:20 |
A clinically translatable super-inert near-infrared fluorescent dye for surgical navigation |
|
|||||
| 7 | 09:20-09:30 |
Advancing Clinical Research in Diabetic Kidney Disease: Experience from the DYNAMO Study |
|
|||||
| 8 | 09:30-09:40 |
Clinical Big Data and Artificial Intelligence-Based Integrated Diagnosis and Treatment for Prostate Cancer |
|
|||||
| 1 | 09:40-09:50 |
AR-degrading peptide, a novel solution for prostate cancer |
|
|||||
| 2 | 09:50-10:00 |
SIRT5-Mediated Desuccinylation of FASN Regulates Lipid Metabolic Reprogramming and Promotes Prostate Cancer Cell Proliferation |
|
|||||
| 3 | 10:00-10:10 |
The DIS3–glycoRNA Axis Drives Early Tumor Immune Evasion by Remodeling DC–T Cell Immune Responses |
|
|||||
| 4 | 10:10-10:20 |
VHL inhibits autophagy and tumor development by modulating ATG14 hydroxylation in a PHD1-dependent manner |
|
|||||
| 5 | 10:20-10:30 |
SLC26A7+ Cancer-Associated Fibroblasts Promote Axitinib Resistance in Renal Cell Carcinoma via TET1 Lactylation Modification |
|
|||||
| 6 | 10:30-10:40 |
Cytoskeletal Protein KRT14 Governs Cisplatin Resistance by Modulating eIF4H-Dependent ACOX2 Translation and Lipid Metabolism in Bladder Cancer |
|
|||||
| 7 | 10:40-10:50 |
A Novel Natural Tumor-Suppressive Micropeptide Removes the TRIM25-Mediated Anti-Ferroptosis Barrier and Inhibits Bladder Cancer Progression |
|
|||||
| 8 | 10:50-11:00 |
Environmental Pollutant DEHP Drives Castration-Resistant Prostate Cancer Progression via OTUB2-Mediated Deubiquitination of MDM2 |
|
|||||
| 1 | 11:00-11:10 |
|
|
|||||
| 2 | 11:10-11:20 |
TE-RPA: A Single-Tube Telomerase Extension-Recombinase Polymerase Amplification-Based Electrochemical Biosensor for Precise Diagnosis of Urothelial Carcinoma |
|
|||||
| 3 | 11:20-11:30 |
Integrative spatial dissection of tumor microenvironment architecture in bladder cancer invasion |
|
|||||
| 4 | 11:30-11:40 |
Epigenomic Analysis Reveals AR-Associated Enhancer RNAs Modulate LTF Transcription to Influence Ferroptosis in Prostate Cancer |
|
|||||
| 5 | 11:50-12:00 |
Exosomal ST6GAL1 from Prostate Cancer Promotes Perineural Invasion by Regulating Neuronal NGF Secretion via the Integrin β1/FAK/ERK Signaling Axis |
|
|||||
| 6 | 11:50-12:00 |
LncCAM6A Promotes Sunitinib Resistance in Renal Cell Carcinoma by Activating Pyrimidine Synthesis via RBM15-Mediated m6A Modification of NAGS |
|
|||||
| 7 | 12:00-12:10 |
Single-Cell Glyco-LacNAc Multi-Omics-Based Development of a Draining Lymph Node-Derived T Cell Therapy for Bladder Cancer |
|
|||||
| 8 | 12:10-12:20 |
The Non-Canonical Function of Claudin-1 Drives Prostate Cancer Lineage Plasticity and Chemotherapy Resistance by Alleviating Lethal Endoplasmic Reticulum Stress |
|
|||||
| 1 | 13:30-13:40 |
Opening Remarks |
|
|||||
| 1 | 13:40-13:50 |
Fasting-Mimicking Diet-Driven Taurocholic Acid Reduction Enhances Renal Cell Carcinoma Immunotherapy by Attenuating MDSC-Mediated Immunosuppression |
|
|||||
| 2 | 13:50-14:00 |
Gut Microbiota Dysbiosis After Androgen Deprivation Promotes Castration-Resistant Prostate Cancer Progression via TMAO-Mediated Remodeling of SPP1⁺ Tumor-Associated Macrophages |
|
|||||
| 3 | 14:10-14:20 |
Single-Cell Spatial Atlas Reveals Prostate Cancer Immune Microenvironment Heterogeneity and Identifies CCL18⁺ Macrophages as a Predictive Biomarker for Immunotherapy Response |
|
|||||
| 4 | 14:20-14:30 |
Wearable Low-Intensity Ultrasound Drives Fibroblasts Toward an FGF10⁺ Phenotype to Promote Postoperative Urethral Remodeling |
|
|||||
| 5 | 14:30-14:40 |
Exploring the Interrelationship Among Metabolic Syndrome, IGF-1, and Benign Prostatic Hyperplasia in a Sprague-Dawley Rat Model |
|
|||||
| 6 | 14:40-14:50 |
Environmental Endocrine-Disrupting Chemical Exposure Promotes Prostate Cancer Progression by Regulating the Tumor Immune Microenvironment |
|
|||||
| 7 | 14:50-15:00 |
Integrated CosMx Spatial Transcriptomics and FFPE Single-Nucleus RNA Sequencing Reveal Perineural Invasion-Associated Tumor Subpopulations and Castration-Resistant Features in Prostate Cancer |
|
|||||
| 8 | 15:00-15:10 |
Break |
||||||
| 1 | 15:10-15:20 |
Exercise Alleviates Benign Prostatic Hyperplasia via Synergistic Serotonylation and Lactylation |
|
|||||
| 2 | 15:20-15:30 |
Cytoplasmic Translocation of SIRT5 Remodels Glycolytic Metabolic Flux to Promote Castration-Resistant Prostate Cancer: Mechanisms and Therapeutic Strategies |
|
|||||
| 3 | 15:30-15:40 |
Multi-Omics Integration Reveals ZDHHC24 Drives Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Regulating Lipid Metabolism |
|
|||||
| 4 | 15:40-15:50 |
YWHAG Promotes Bladder Cancer Progression by Competitively Inhibiting FBXL7-Mediated Ubiquitination of BCLAF1 |
|
|||||
| 5 | 15:50-16:00 |
HE Slide-Based Spatial Gene Expression Prediction Model Deciphers Spatial Transcriptomic Features and Clinical Significance in Bladder Cancer |
|
|||||
| 6 | 16:00-16:10 |
Lactylation Atlas of Clear Cell Renal Cell Carcinoma Reveals Ferritin Lactylation Regulates Ferroptosis by Inhibiting Ubiquitin-Proteasome Degradation |
|
|||||
| 7 | 16:10-16:20 |
Single-Cell Sequencing Reveals SERPINE1⁺ Tumor Cells Remodel a Treg-Enriched Microenvironment via the JAK2/STAT3/TGF-β Axis to Drive Neoadjuvant Immunotherapy Resistance in Renal Cell Carcinoma |
|
|||||
| 1 | 16:40-16:50 |
UBTF Remodels the Androgen Receptor Chromatin Binding Landscape and Activates DNA Damage Repair Programs to Promote Prostate Cancer Progression |
|
|||||
| 2 | 16:50-17:00 |
GATAD1 Downregulation in Adrenal DLPC Promotes Ectopic Calcification of Arteries and Renal Interstitium |
|
|||||
| 3 | 17:00-17:10 |
YTHDF3 Facilitates Cytoskeletal Remodeling to Promote Mitochondrial Transfer and CD8⁺ T Cell Exhaustion in Prostate Cancer |
|
|||||
| 4 | 17:10-17:20 |
Mechanotransduction-Translation Coupling Mediates Cavernous Fibroblast Phenotypic Switching: A New Perspective on Diabetic Erectile Dysfunction Pathogenesis |
|
|||||
| 5 | 17:20-17:30 |
Application Value of ADAM19 in CTC EMT Subtyping and Prognostic Assessment for Renal Cell Carcinoma |
|
|||||
| 6 | 17:30-17:40 |
Targeting AREG⁺ Dendritic Cells Alleviates Renal Fibrosis Induced by Ischemia-Reperfusion Injury |
|
|||||
| 7 | 17:40-17:50 |
Therapeutic Effect and Preliminary Mechanisms of FAST Whole-Cell Tumor Vaccine Combined with SBRT in Renal Cell Carcinoma |
|
|||||
| 8 | 17:50-18:00 |
Identification of CD276 Ligands and Receptors and Exploration of Their Biological Functions in Urological Tumors |
|
|||||
| 1 | 18:00-18:10 |
Summary |
|
|||||
| 1 | 08:00-08:20 |
Opening Remarks |
|
|||||||||||
| 1 | 08:20-08:30 |
2026 Yat-sen Review of Bladder Cancer Progress |
|
|||||||||||||||||
| 2 | 08:30-08:40 |
Can hormone therapy alone achieve long-term remission? Post-hoc analysis of the EMBARK study: Evaluating sustained PSA <0.2 ng/mL with testosterone recovery after treatment cessation |
|
|||||||||||||||||
| 3 | 08:40-08:50 |
Challenges and Opportunities in the Diagnosis and Treatment of Prostate Cancer |
|
|||||||||||||||||
| 4 | 08:50-09:00 |
Management of urological nightmare cases: Left renal artery root hemorrhage and management of giant bilateral renal tumors involving the superior mesenteric artery |
|
|||||||||||||||||
| 5 | 09:00-09:10 |
Introduction to European Urology Oncology (EUO) |
|
|||||||||||||||||
| 6 | 09:10-09:20 |
Current Landscape of Biomarker Testing in Urologic Malignancies |
|
|||||||||||||||||
| 7 | 09:20-09:30 |
Discussion |
|
|||||||||||||||||
| 1 | 09:30-09:40 |
Liquid biopsy diagnostic technology for prostate cancer based on platelet ultrastructure |
|
|||||||||||||||||
| 2 | 09:40-09:50 |
Prostate-specific antigen kinetics and deep/ultra-deep response to darolutamide plus androgen deprivation therapy in real-world metastatic hormone-sensitive prostate cancer without docetaxel |
|
|||||||||||||||||
| 3 | 09:50-10:00 |
Modern Active Surveillance in Prostate Cancer |
|
|||||||||||||||||
| 4 | 10:00-10:10 |
Biochemical Recurrence After Radical Prostatectomy in the PSMA-PET Era: Who, When and How to Treat? |
|
|||||||||||||||||
| 5 | 10:10-10:20 |
From PSA elevation to histological confirmation: the prostate cancer continuum |
|
|||||||||||||||||
| 6 | 10:20-10:30 |
Evaluation of immediate urinary continence efficacy of domestic single-port robotic radical prostatectomy combined with intraoperative umbilical artery ligament suspension: A report of 17 cases |
|
|||||||||||||||||
| 7 | 10:30-10:40 |
Discussion |
|
|||||||||||||||||
| 1 | 10:40-10:50 |
Population-Based Prostate Cancer Screening in Europe: Lessons Learned and Future Directions |
|
|||||||||||||||||
| 2 | 10:50-11:00 |
How to manage recurrences after focal therapy in prostate cancer? |
|
|||||||||||||||||
| 3 | 11:00-11:10 |
The currently available intravesical treatments for BCG-refractory NMIBC and what lies ahead |
|
|||||||||||||||||
| 4 | 11:10-11:20 |
Efficacy and safety of cadonilimab combined with disitamab vedotin in perioperative treatment of HER2-expressing muscle-invasive bladder cancer: Results of a phase II clinical study |
|
|||||||||||||||||
| 5 | 11:20-11:30 |
Association of dynamic circulating tumor DNA monitoring before and after radical cystectomy with recurrence-free survival in bladder cancer patients |
|
|||||||||||||||||
| 6 | 11:30-11:40 |
Efficacy and safety of disitamab vedotin combined with tislelizumab as adjuvant therapy after radical nephroureterectomy for HER2-expressing upper tract urothelial carcinoma: A prospective phase II controlled study |
|
|||||||||||||||||
| 7 | 11:40-11:50 |
Discussion |
|
|||||||||||||||||
| 1 | 12:30-12:45 |
Recent Advances in Advanced Renal Cell Carcinoma Research |
|
|||||
| 1 | 12:45-13:00 |
The New Era of Local Advanced and Metastatic Urothelial Cancer Treatment by Bispecific Antibody-Drug Conjugates |
|
|||||
| 1 | 13:00-13:15 |
From Evidence to Practice: A Decade of Advancement in Renal Cell Carcinoma Management |
|
|||||
| 1 | 13:15-13:30 |
Treatment Timing and Efficacy Evaluation of Radium-223 |
|
|||||
| 1 | 13:30-13:40 |
Opening Remarks |
|
|||||
| 1 | 13:40-13:50 |
Benzo[a]pyrene drives bladder cancer progression and immunotherapy resistance by disrupting the tryptophan-immune axis through depletion of gut Bacteroides |
|
||||||||||||||
| 2 | 13:50-14:00 |
Application of a novel original isoperistaltic dual-input loop ileal orthotopic neobladder in radical cystectomy (A report of 28 cases) |
|
||||||||||||||
| 3 | 14:00-14:10 |
Clinical study of oncolytic adenovirus Oncorine (H101) combined with PD-1 inhibitors in patients with non-muscle-invasive bladder cancer (NMIBC) failing BCG treatment |
|
||||||||||||||
| 4 | 14:10-14:20 |
PRMT1-regulated arginine methylation of SF3A2 promotes cisplatin resistance in bladder cancer by enhancing SP1 alternative splicing |
|
||||||||||||||
| 5 | 14:20-14:30 |
"Zero-background" second near-infrared fluorescent probes for precision intraoperative navigation across pan-cancers |
|
||||||||||||||
| 6 | 14:30-14:40 |
Discussion |
|
||||||||||||||
| 1 | 14:40-14:50 |
Surgical Treatment of Renal Cell Carcinoma with IVC Involvement: a Single Center Experience |
|
||||||||||||||
| 2 | 14:50-15:00 |
Functional phenotypic drug sensitivity testing based on humanized tumor cell clusters (PTCs): Precision navigation for individualized decision-making in neoadjuvant therapy for renal cell carcinoma |
|
||||||||||||||
| 3 | 15:00-15:10 |
Spatiotemporal mechanism of mechanical stress-remodeling tertiary lymphoid structures driving renal cancer venous tumor thrombus evolution and targeted-immunotherapy resistance |
|
||||||||||||||
| 4 | 15:10-15:20 |
SAV1 membrane localization imbalance mediates collagen I-induced Hippo pathway inactivation and promotes lipid metabolism reprogramming in clear cell renal cell carcinoma |
|
||||||||||||||
| 5 | 15:20-15:30 |
Correlation analysis of disease progression patterns and prognosis with genomic/transcriptomic features in metastatic non-clear cell renal cell carcinoma |
|
||||||||||||||
| 6 | 15:30-15:40 |
Discussion |
|
||||||||||||||
| 1 | 15:50-16:00 |
How imaging is shaping prostate cancer management |
|
|||||||||||||||||
| 2 | 16:00-16:10 |
Intraoperative molecular imaging for margin assessment in high-risk prostate cancer |
|
|||||||||||||||||
| 3 | 16:10-16:20 |
Organ-Sparing Focal Therapy vs Radical Prostatectomy for Localized Prostate Cancer |
|
|||||||||||||||||
| 4 | 16:20-16:30 |
Real-time intraoperative assessment of tumor-positive surgical margins during radical prostatectomy: A phase II, single-arm, open-label clinical trial of PSMA-targeted fluorescent contrast agents |
|
|||||||||||||||||
| 5 | 16:30-16:40 |
SIRT5-mediated desuccinylation of HADHA K644 reprograms fatty acid oxidation-STAT3 lipid metabolism axis to drive castration-resistant prostate cancer resistance and progression |
|
|||||||||||||||||
| 6 | 16:40-16:50 |
Discussion |
|
|||||||||||||||||
| 1 | 16:50-17:00 |
Risk factors and multimodal preoperative prediction of ISUP grade upgrading after radical prostatectomy in prostate cancer patients with preoperative tPSA <10 ng/mL: A single-center cohort study based on clinical, MRI, and biopsy information |
|
||||||||||||||
| 2 | 17:00-17:10 |
Artificial Intelligence-Driven Quantitative Histologic Grading and Prognostic Stratification for Clear Cell Renal Cell Carcinoma |
|
||||||||||||||
| 3 | 17:10-17:20 |
Multi-center retrospective study: Clinical characteristics and prognostic analysis of patients with renal metastases |
|
||||||||||||||
| 4 | 17:20-17:30 |
"Subtype map" of lymph node dissection in renal cell carcinoma: Station-level evidence from 394 simultaneous dissections |
|
||||||||||||||
| 5 | 17:30-17:40 |
Clinical pathological characteristics, diagnosis and treatment analysis of renal epithelioid angiomyolipoma |
|
||||||||||||||
| 6 | 17:40-17:50 |
Discussion |
|
||||||||||||||
| 1 | 08:00-08:05 |
Opening Remarks |
|
|||||
| 2 | 08:05-08:10 |
Opening Remarks |
|
|||||
| 1 | 08:10-08:25 |
Enfortumab Vedotin + Pembrolizumab in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer: Exploratory Analyses Based on Disease-Related Characteristics from EV-302 |
|
||||||||||||||||||||
| 2 | 08:25-08:40 |
Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient de novo metastatic hormone-sensitive prostate cancer (mHSPC): Phase III CAPItello-281 Chinese subgroup analysis |
|
||||||||||||||||||||
| 3 | 08:40-08:55 |
Phase I clinical study of LACO-Stim modified targeted CD70 CAR-T cells in the treatment of metastatic renal clear cell carcinoma |
|
||||||||||||||||||||
| 4 | 08:55-09:10 |
Early precision prevention and control of lung cancer |
|
||||||||||||||||||||
| 5 | 09:10-09:25 |
Prospective, single-arm Phase II study of disitamab vedotin in locally advanced or metastatic extramammary Paget's disease with high HER2 expression (Formula-10) |
|
||||||||||||||||||||
| 6 | 09:25-09:40 |
Radioligand Therapy Clinical Trials: An Investigator and Drug Development Perspective |
|
||||||||||||||||||||
| 7 | 09:40-09:55 |
Discussion |
|
||||||||||||||||||||
| 1 | 09:55-10:10 |
Efficacy of debulking radical prostatectomy for patients with high tumor burden metastatic prostate cancer achieving deep PSA remission after systemic treatment: a prospective multicenter cohort study |
|
||||||||||||||||||||
| 2 | 10:10-10:25 |
Clinical exploration of posterior approach radical prostatectomy |
|
||||||||||||||||||||
| 3 | 10:25-10:40 |
Efficacy and Safety Evaluation of FANS f-URS Versus PCNL in the Treatment of 3-4cm Renal Stones - Preliminary Results of a Multi-Center Study |
|
||||||||||||||||||||
| 4 | 10:40-10:55 |
Study on the diagnostic efficacy of molecular imaging targeting CAⅨ in renal clear cell carcinoma |
|
||||||||||||||||||||
| 5 | 10:55-11:10 |
Intravesical Disitamab Vedotin (RC48) for BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: A Multicenter Phase I Trial |
|
||||||||||||||||||||
| 6 | 11:10-11:25 |
Emerging therapies in NMIBC: from clinical trials to future practice |
|
||||||||||||||||||||
| 7 | 11:25-11:40 |
Discussion |
|
||||||||||||||||||||
| 1 | 11:40-12:30 |
Roundtable Discussion |
|
|||||||||||||||||||||||
| 1 | 13:30-13:36 |
Genomic and Epigenomic Approaches to Target Discovery and Therapeutic Development |
|
||||||||||||||||||||
| 2 | 13:36-13:42 |
Multimodal Fusion Ultrasound for Precision Navigation |
|
||||||||||||||||||||
| 3 | 13:42-13:48 |
Prospective Phase II Study of Neoadjuvant Targeted Immunotherapy Combined with Response-Adaptive Nephron-Sparing Strategy for High-Risk Upper Urinary Tract Urothelial Carcinoma |
|
||||||||||||||||||||
| 4 | 13:48-13:54 |
Ultrasound-guided balloon occlusion for hybrid partial nephrectomy: a non-randomized controlled trial |
|
||||||||||||||||||||
| 5 | 13:54-14:00 |
Precision antegrade robotic inguinal lymph node dissection under fluorescence imaging combined with color Doppler ultrasound localization |
|
||||||||||||||||||||
| 6 | 14:00-14:06 |
Artificial intelligence based augmented reality navigation in minimally invasive partial nephrectomy |
|
||||||||||||||||||||
| 7 | 14:06-14:12 |
Diagnostic efficacy and safety of PSMA-targeted near-infrared fluorescent contrast agent DGPR1008 in robotic-assisted radical prostatectomy: a single-center phase II clinical trial |
|
||||||||||||||||||||
| 8 | 14:12-14:18 |
Clinical research on bladder preservation with MIBC patients |
|
||||||||||||||||||||
| 9 | 14:18-14:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 14:30-14:36 |
Prospective, multicenter study on the non-invasive diagnosis of urothelial carcinoma through urine SIX6 methylation detection |
|
||||||||||||||||||||
| 2 | 14:36-14:42 |
Deficiencies in the diagnostic system for prostate cancer - A series of explorations to enhance the diagnostic accuracy of prostate cancer |
|
||||||||||||||||||||
| 3 | 14:42-14:48 |
Integrated diagnostic study of urine metabolomics combined with MRI radiomics in patients with prostate cancer |
|
||||||||||||||||||||
| 4 | 14:42-14:54 |
Urinary detection based on methylation for the diagnosis and recurrence monitoring of urothelial carcinoma: a multicenter, prospective clinical study |
|
||||||||||||||||||||
| 5 | 14:54-15:00 |
Application of dual-modal liquid biopsy based on CRISPR/Cas12a in precision diagnosis of prostate cancer |
|
||||||||||||||||||||
| 6 | 15:00-15:06 |
Multi-center research, development, and validation of UPGRADE-Dx: A non-invasive prostate cancer precision screening and biopsy guidance model based on low-abundance proteomics in urine |
|
||||||||||||||||||||
| 7 | 15:06-15:12 |
Combined application of GPR143, SV2B, and NMRK2 immunohistochemical markers effectively distinguishes TFE3-rearranged renal cell carcinoma from renal clear cell carcinoma and papillary renal cell carcinoma: a multicenter study |
|
||||||||||||||||||||
| 8 | 15:12-15:18 |
Research on the application value of MRI artificial intelligence in precise biopsy diagnosis of prostate cancer: a prospective diagnostic trial |
|
||||||||||||||||||||
| 9 | 15:18-15:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 15:30-15:36 |
Study on the necessity of pelvic lymph node dissection in radical cystectomy for high-risk non-muscle-invasive bladder cancer - a prospective multicenter study |
|
||||||||||||||||||||
| 2 | 15:36-15:42 |
Darolutamide combined with ADT versus Bicalutamide combined with ADT as adjuvant therapy after radical surgery for high-risk localized prostate cancer: Interim analysis |
|
||||||||||||||||||||
| 3 | 15:42-15:48 |
Efficacy and safety of a domestic water vapor thermal therapy system in patients with benign prostatic hyperplasia: a prospective, multicenter, single-blind, randomized controlled trial |
|
||||||||||||||||||||
| 4 | 15:48-15:54 |
The effect of a treatment method based on lipus innovative technology on the recovery of urinary incontinence after radical androgen deprivation therapy (RARP): a randomized, double-blind, prospective, multicenter clinical trial |
|
||||||||||||||||||||
| 5 | 15:54-16:00 |
A multi-center randomized controlled study on percutaneous nephrolithotomy guided by CT-ultrasound fusion and conventional ultrasound |
|
||||||||||||||||||||
| 6 | 16:00-16:06 |
Safety study of autologous dendritic cell vaccine Prolevis in metastatic castration-resistant prostate cancer patients who have failed standard treatment: a multicenter, non-randomized, open-label, dose-escalation Phase I clinical trial |
|
||||||||||||||||||||
| 7 | 16:06-16:12 |
Evaluation of early efficacy of domestic prostate suspension system in the treatment of benign prostatic hyperplasia: a multicenter prospective randomized parallel controlled study |
|
||||||||||||||||||||
| 8 | 16:12-16:18 |
A prospective, multicenter, randomized controlled clinical trial on the prevention of GnRH agonist-induced flare-up effects with rivarubicin |
|
||||||||||||||||||||
| 9 | 16:18-16:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 16:30-16:36 |
Application of Prostate-Specific Membrane Antigen (PSMA) PET/MRI-Guided Targeted Prostate Biopsy in Patients with PI-RADS Score ≤3 and Previous Negative Biopsy: A Single-Center, Prospective, Open-Label, Randomized Controlled Study |
|
||||||||||||||||||||
| 2 | 16:36-16:42 |
Tislelizumab Combined with Radiotherapy for Bladder Preservation in High-Risk Non-Muscle-Invasive Bladder Cancer Following BCG Failure: A Single-Arm, Phase 2 Clinical Trial |
|
||||||||||||||||||||
| 3 | 16:42-16:48 |
resection followed by sequential endocrine therapy for high tumor burden metastatic prostate cancer: a single-center prospective non-randomized controlled study |
|
||||||||||||||||||||
| 4 | 16:48-16:54 |
Phase II clinical study of CD70 immuno-PET imaging for the diagnosis of renal clear cell carcinoma |
|
||||||||||||||||||||
| 5 | 16:54-17:00 |
Prospective randomized clinical study on the selection of bladder instillation chemotherapy drugs guided by patient-derived tumor-like cell clusters after surgery for non-muscle-invasive bladder cancer |
|
||||||||||||||||||||
| 6 | 17:00-17:06 |
Phase Ia clinical trial of intravesical instillation of recombinant oncolytic adenovirus KD01 for the treatment of high-risk non-muscle-invasive bladder cancer: a single-center, open-label, non-randomized study |
|
||||||||||||||||||||
| 7 | 17:06-17:12 |
Detection characteristics of prostatic intraductal carcinoma and its association with biochemical recurrence after radical prostatectomy: a single-center retrospective study based on 7060 specimens |
|
||||||||||||||||||||
| 8 | 17:12-17:18 |
The application value of targeted biopsy based on real-time radioactive measurement with 123I-PSMA-7 in the diagnosis of clinically significant prostate cancer: a single-center prospective exploratory study |
|
||||||||||||||||||||
| 9 | 17:18-17:30 |
Discussion |
|
||||||||||||||||||||
| 1 | 17:30-17:36 |
Research on Prostate Biopsy Decision-making Model Based on Morning Urine PCA3 and mpMRI Features |
|
||||||||||||||||||||
| 2 | 17:36-17:42 |
Single-center, retrospective cohort analysis of pelvic lipomatosis - Renji experience |
|
||||||||||||||||||||
| 3 | 17:42-17:48 |
The current application status and pathological benefits of lymph node dissection in radical prostatectomy: a retrospective study based on 1861 cases from a single center |
|
||||||||||||||||||||
| 4 | 17:48-17:54 |
High-frequency mutations and genotype-phenotype analysis of the VHL gene: a retrospective study based on 820 Chinese patients with von Hippel-Lindau syndrome |
|
||||||||||||||||||||
| 5 | 17:54-18:00 |
A 12-year multicenter review of laparoscopic or robotic-assisted laparoscopic endovascular stenting for the treatment of type 1 nutcracker syndrome |
|
||||||||||||||||||||
| 6 | 18:00-18:06 |
Clinical Research on the Treatment of Ureteral Polyp with Lingual Mucosa Ureteroplasty |
|
||||||||||||||||||||
| 7 | 18:06-18:12 |
Analysis of clinical epidemiological characteristics and regional heterogeneity of prostate cancer in Jiangsu Province: based on a survey of 3,717 patients from 17 centers |
|
||||||||||||||||||||
| 8 | 18:12-18:18 |
The prognostic significance of pathological nerve invasion in prostate cancer: when coexistent with positive resection margins, it significantly promotes castration-resistant transformation, a multi-center ten-year follow-up study |
|
||||||||||||||||||||
| 9 | 18:18-18:24 |
Preliminary clinical observation on the safety and efficacy of Rezūm® thermal vapor ablation therapy in patients with benign prostatic hyperplasia and comorbid high-risk cardiovascular diseases: a single-arm, single-center retrospective study |
|
||||||||||||||||||||
| 10 | 18:24-18:36 |
Discussion |
|
||||||||||||||||||||
| 1 | 08:00-08:10 |
Opening Remarks |
|
||||||||||||||
| 1 | 08:10-08:20 |
CUA Urinary Tract Reconstruction Committee: Buccal Mucosal Graft Multicenter Study and Platform Development |
|
|||||
| 2 | 08:20-08:30 |
Tongue Mucosa and Penile Skin Flap Graft Urethroplasty for Anterior Male Urethral Stricture |
|
|||||
| 3 | 08:30-08:40 |
Application of Ureteral End‑to‑side Anastomosis in Upper Urinary Tract Reconstructive Surgery |
|
|||||
| 4 | 08:40-08:50 |
Urinary Tract Reconstruction in the New Minimally‑invasive Era: Reflections and Practices |
|
|||||
| 5 | 08:50-09:00 |
Experience with Ureteral‑Lower Calyceal Anastomosis for Hilar Ureteral Stricture |
|
|||||
| 6 | 09:00-09:10 |
Robot‑Assisted Surgery for Adult Duplex Kidney and Ureteral Duplication Anomalies: Comparison of Functional Recovery and Perioperative Outcomes between Heminephrectomy and Urinary Tract Reconstructive Surgery |
|
|||||
| 7 | 09:10-09:20 |
Drug-eluting balloons for ureteral strictures - A tool or a tale? |
|
|||||
| 1 | 09:20-09:30 |
Complete Dorsal‑Approach Posterior Urethroplasty for Posterior Urethral Stricture Secondary to Pelvic Fracture Urethral Injury: A Reconstructive Technique Preserving Anatomy and Blood Supply |
|
|||||
| 2 | 09:30-09:40 |
The application value of single-port surgical robots in upper urinary tract reconstruction surgery |
|
|||||
| 3 | 09:40-09:50 |
Management of Complex Anterior Urethral Strictures - Cameroon Experience |
|
|||||
| 4 | 09:50-10:00 |
Robot‑Assisted Laparoscopic Multi‑arm Single‑port Transanal Repair of Vesicorectal Fistula after Sigmoid Augmentation Cystoplasty: A Case Report |
|
|||||
| 5 | 10:00-10:10 |
Efficacy Evaluation of Modified Circular Penile Skin Flap for Anterior Urethral Stricture |
|
|||||
| 6 | 10:10-10:20 |
Application of Mixed Reality 3D Visualization Technology in Reconstruction of Posterior Urethral Disruption Secondary to Pelvic Fracture |
|
|||||
| 7 | 10:20-10:30 |
Application Study of a New Pelvi‑urethral Classification Based on Proximal Urethral Depth and Pubic Ramus Width for Predicting Surgical Difficulty of Posterior Urethral Stricture after Pelvic Fracture Urethral Injury |
|
|||||
| 1 | 10:30-10:39 |
A clinical entity of multiple ureteral fibroepithelial polyps with annular stenosis and tortuosity: clinical features and management considerations |
|
|||||
| 2 | 10:39-10:48 |
Intracorporeal Neobladder Reconstruction After Robot-Assisted Radical Cystectomy: Surgical Principles, Technical Steps, and Functional Outcomes of the FloRIN Technique |
|
|||||
| 3 | 10:48-10:57 |
Nurenburg experience in Robotic assisted pyeloplasty with simultaneous intraoperativ endoscopic stone treatment |
|
|||||
| 4 | 10:57-11:06 |
Balanced Distension and Relaxation — A Retrospective Controlled Study of Preoperative Management Strategy for Reconstructive Repair with Selective "Ureteral Rest" Based on the Concept of "Ureteral Tissue Reserve" |
|
|||||
| 5 | 11:06-11:15 |
Laparoscopic Calyco‑ureteroplasty for Complex Proximal Ureteral Stricture |
|
|||||
| 6 | 11:15-11:24 |
Clinical Characteristics and Standardized Diagnosis and Treatment Protocol in 370 Patients with Radiation‑Induced Ureteral Stricture: A Multicenter, Bidirectional Cohort Study |
|
|||||
| 7 | 11:24-11:33 |
Study on Magnetic Compression Technique for Mid‑ureteral Stricture |
|
|||||
| 1 | 11:33-11:42 |
The Nightmare of Endoscopic Surgery: What We Can do to Timely Control Injury after Ureteral Avulsion |
|
|||||
| 2 | 11:42-11:51 |
The Crossing Point: A Common Anatomical Hub of Impacted Ureteral Calculus and Stone‑Associated Ureteral Stricture |
|
|||||
| 3 | 11:51-12:00 |
Development and Validation of an Explainable Multimodal Radiomics‑Based Artificial Intelligence‑Assisted Diagnostic System for Pelvic Lipomatosis: A Multicenter Study |
|
|||||
| 4 | 12:00-12:09 |
Comparison of Efficacy of Discontinuous versus Non‑discontinuous Buccal Mucosal Graft Combined with Posterior Wall Reconstruction Ureteral Augmentoplasty for Complex Ureteral Stricture: A Propensity‑Score‑Matched Study |
|
|||||
| 5 | 12:09-12:18 |
De‑stenting Efficacy Analysis of Self‑expandable Metallic Ureteral Stents for Complex Ureteral Stricture: A Retrospective Single-center Study |
|
|||||
| 6 | 12:18-12:27 |
Role of the CXCL8/NF‑κB Signaling Axis in Ureteral Stricture Formation after Holmium Laser Lithotripsy and Intervention Study of Targeted Drug‑eluting Stents |
|
|||||
| 7 | 12:27-12:36 |
Preliminary Exploration and Efficacy Analysis of Robot‑Assisted Laparoscopic Re‑implantation of Ureter into Bladder |
|
|||||
| 1 | 13:20-13:30 |
Opening Remarks |
|
||||||||
| 1 | 13:30-13:42 |
3-Year Follow-Up Study on Partial Resection Versus Total Resection of Aldosterone-Producing Adenomas |
|
|||||||||||||||||
| 2 | 13:42-13:54 |
⁶⁸Ga-Pentixafor PET/CT-Guided Retroperitoneoscopic Single-Plane Partial Adrenalectomy for Unilateral Solitary Aldosterone-Producing Adenoma: Perioperative Safety and Medium-Term Functional Outcomes |
|
|||||||||||||||||
| 3 | 13:54-14:06 |
Mechanisms of Formation of the Immunosuppressive Microenvironment in Adrenocortical Carcinoma and Potential Intervention Strategies |
|
|||||||||||||||||
| 4 | 14:06-14:18 |
Preoperative Differential Value of Serum Lactate Dehydrogenase for Adrenocortical Carcinoma: A Retrospective Cohort Study |
|
|||||||||||||||||
| 5 | 14:18-14:30 |
Study on the Characteristics and Clinical Significance of "Microenvironment Adaptation" of Adrenal Metastatic Carcinoma Based on Transcriptomics and Metabolomics |
|
|||||||||||||||||
| 6 | 14:30-14:40 |
Discussion |
|
|||||||||||||||||
| 1 | 14:40-14:52 |
Is Preoperative Preparation Required for Patients with Small Pheochromocytoma? —— A Multicenter Study Based on 57 Patients |
|
|||||||||||||||||
| 2 | 14:52-15:04 |
Construction and Validation of a Preoperative Prediction Model for the Surgical Complexity of Giant Pheochromocytoma |
|
|||||||||||||||||
| 3 | 15:04-15:16 |
Establishment of a Complexity Grading System for Pheochromocytoma and Paraganglioma and Its Impact on Surgical Planning and Perioperative Outcomes |
|
|||||||||||||||||
| 4 | 15:16-15:28 |
The clinical differences between patients with pheochromocytoma with hypertension and those with normotension |
|
|||||||||||||||||
| 5 | 15:28-15:40 |
Clinical Analysis of 121 Cases of Pheochromocytoma/Paraganglioma and Systematic Evaluation of Misdiagnosis, Missed Diagnosis and Delayed Diagnosis |
|
|||||||||||||||||
| 6 | 15:40-15:50 |
Discussion |
|
|||||||||||||||||
| 1 | 15:50-16:02 |
Clinical Application of Robot-assisted Laparoscopic Retroperitoneal Tumor Resection Combined with Intraoperative Intelligent Navigation in the Treatment of Retroperitoneal Tumors in the Crossroad Area Posterior to the Inferior Vena Cava-Bilateral Renal Veins |
|
|||||||||||||||||
| 2 | 16:02-16:14 |
Clinical Experience and Treatment Strategies for Retroperitoneal Tumors Complicated with Venous Tumor Thrombus |
|
|||||||||||||||||
| 3 | 16:14-16:26 |
Application of Combined Major Vascular Resection and Reconstruction in Open Surgery for Giant Adrenal Tumors: A Clinical Analysis of 23 Cases |
|
|||||||||||||||||
| 4 | 16:26-16:38 |
Discussion on the Application of Versius Single-port Serpentine Arm Robot-assisted Adrenalectomy (with a Report of 11 Cases) |
|
|||||||||||||||||
| 5 | 16:38-16:50 |
Preoperative Scoring System for RLA Difficulty Based on Tumor Size, Location and Pathological Type: A Single-Center Retrospective Study |
|
|||||||||||||||||
| 6 | 16:50-17:02 |
From Preoperative Planning to Postoperative Assistance: Full-Process Multidisciplinary Management of Patients with Adrenal Tumors and Tumor Thrombus |
|
|||||||||||||||||
| 7 | 17:02-17:14 |
Discussion |
|
|||||||||||||||||
| 8 | 17:14-17:20 |
Summary |
||||||||||||||||||
| 1 | 08:00-08:05 |
Opening Remarks |
|
|||||
| 2 | 08:05-08:10 |
|
|
|||||
| 1 | 08:15-08:25 |
Interpretation of the 2026 Guidelines for Urostomy Nursing |
|
|||||
| 2 | 08:25-08:35 |
Interpretation of the 2026 Guidelines for Incontinence Nursing |
|
|||||
| 3 | 08:35-08:42 |
The Impact of Social Media on Social Reintegration Among Young and Middle-Aged Patients with Urological Cancer: A Qualitative Study Based on Interpretive Description |
|
|||||
| 4 | 08:42-08:49 |
Dynamic Trajectories and Longitudinal Evolution of Symptom Clusters During Intravesical Instillation Therapy in Patients with Bladder Cancer |
|
|||||
| 5 | 08:49-08:56 |
Construction and Application of a Perioperative Nursing Risk Prediction and Early Warning Model for Patients with Prostate Cancer |
|
|||||
| 6 | 08:56-09:03 |
Trajectories of Urinary Incontinence in Patients After Laparoscopic Radical Prostatectomy Based on Latent Class Growth Modeling |
|
|||||
| 7 | 09:03-09:10 |
|
|
|||||
| 8 | 09:10-09:15 |
Discussion and Commentary |
||||||
| 1 | 09:15-09:22 |
Construction and Preliminary Application of a Navigation Nursing Model for Patients with Bladder Cancer and Abdominal Wall Stoma Based on Swanson's Theory of Caring |
|
|||||
| 2 | 09:22-09:29 |
Latent Profile Analysis and Influencing Factors of Self-Management Behaviors in Patients with Urinary Stoma During the Recovery Period After Bladder Cancer Surgery Based on the ABC-X Model |
|
|||||
| 3 | 09:29-09:36 |
Effectiveness of Nurse-Led Self-Management Interventions for Bladder Cancer Patients with Urostomy: A Systematic Review and Meta-Analysis |
|
|||||
| 4 | 09:36-09:43 |
Application Effect of a Nursing Model Based on Orlando's Nursing Process Theory in the Perioperative Period of Patients Undergoing Radical Cystectomy and Urinary Diversion |
|
|||||
| 5 | 09:43-09:50 |
Effect of an AI-Generated Digital and Intelligent Ostomy Management Platform in Postoperative Patients with Bladder Cancer Ostomy |
|
|||||
| 6 | 09:50-09:57 |
Change Trajectories and Influencing Factors of Self-Acceptance in Patients with Permanent Urinary Stoma |
|
|||||
| 7 | 09:57-10:00 |
Discussion and Commentary |
||||||
| 1 | 10:00-10:07 |
Evidence Translation and Application of a Self-Management Program for Urinary Incontinence in Patients After Radical Prostatectomy |
|
|||||
| 2 | 10:07-10:14 |
Efficacy of a Computerized Rehabilitation System on Post-Prostatectomy Urinary Continence: A Randomized Controlled Trial |
|
|||||
| 3 | 10:14-10:21 |
Epidemiological Characteristics and Risk Predictors of Urinary Incontinence Severity Among Older Adults in Elderly Medical and Nursing Institutions in Shanghai |
|
|||||
| 4 | 10:21-10:28 |
A Qualitative User Persona Study on Self-Management of Pelvic Floor Muscle Training in Postoperative Patients with Prostate Cancer |
|
|||||
| 5 | 10:28-10:35 |
Application of the BOPPPS Dual-Track Intervention Model in Improving Urinary Incontinence and Social Avoidance After Radical Prostatectomy |
|
|||||
| 6 | 10:35-10:42 |
Construction of a Patient Journey Map for Prostate Cancer Diagnosis and Treatment: A Qualitative Study |
|
|||||
| 7 | 10:42-10:45 |
Discussion and Commentary |
||||||
| 1 | 10:45-10:52 |
Identifying Toxicity Phenotypes and Hub Symptoms in Patients With Bladder Cancer Receiving PD-1 Inhibitors: A Symptom Cluster and Network Analysis |
|
|||||
| 2 | 10:52-10:59 |
|
|
|||||
| 3 | 10:59-11:06 |
Clinical Study of Auricular Acupoint Pressing Combined with Pelvic Floor Muscle Training for Urinary Incontinence After Radical Prostatectomy |
|
|||||
| 4 | 11:06-11:13 |
Clinical Value of Acupoint Mechanical Stimulation-Mediated Neuromodulatory Intervention in Chronic Pelvic Pain Syndrome: A Single-Center Randomized Controlled Study |
|
|||||
| 5 | 11:13-11:20 |
Comparative efficacy of traditional Chinese medicine-based interventions for erectile dysfunction: an exploratory systematic review and network meta-analysis |
|
|||||
| 6 | 11:20-11:27 |
Effect of Stratified Nursing for Immune-Related Adverse Events (irAEs) Combined with Psychological Intervention on Quality of Life in Patients with Advanced Prostate Cancer |
|
|||||
| 7 | 11:27-11:30 |
Discussion and Commentary |
||||||
| 1 | 11:30-11:37 |
Mediating model of social appearance anxiety and self-concealment between body image and social alienation in patients with urinary stoma |
|
|||||
| 2 | 11:37-11:44 |
Best Evidence Summary of Exercise Prescriptions for Androgen Deprivation Therapy-Related Fatigue in Patients with Prostate Cancer Based on Dose-Response |
|
|||||
| 3 | 11:44-11:51 |
A Longitudinal Cross-Lagged Study of Dyadic Coping, Intimate Relationship Quality, and Psychosocial Adjustment Among Patients with Prostate Cancer and Their Spouses |
|
|||||
| 4 | 11:51-11:58 |
Bidirectional Longitudinal Associations Among Health-Related Quality of Life, Emotional Expressivity, and Readiness to Return to Work in Patients with Non–Muscle-Invasive Bladder Cancer Receiving Intravesical Therapy: A Three-Wave Cohort Study |
|
|||||
| 5 | 11:58-12:05 |
Moderating Mechanisms of Psychological Resilience and Social Support in Influencing Factors of Financial Toxicity Among Patients with Bladder Cancer |
|
|||||
| 6 | 12:05-12:12 |
Effect of Financial Toxicity on Quality of Life in Patients with Bladder Cancer: Mediating Roles of Social Support and Sense of Coherence |
|
|||||
| 7 | 12:12-12:15 |
Discussion and Commentary |
||||||
| 1 | 13:00-13:07 |
Construction and Application of Graded Rewarming Technology for Postoperative Hypothermia After Prostate Enucleation |
|
|||||
| 2 | 13:07-13:14 |
Application of an Intelligent Pelvic Floor Muscle Training Follow-Up System Based on MR and a Transparent Human Body Model in Patients with Urinary Incontinence After Prostate Surgery |
|
|||||
| 3 | 13:14-13:21 |
Synergistic Intervention from the Perspective of Psychosocial Oncology: Constructing a Patient-Centered Postoperative Support Model for Prostate Cancer — A Structured Program Based on the Timing Theory and Exploration of Its Multiple Mechanisms |
|
|||||
| 4 | 13:21-13:28 |
Development and Preliminary Application of a Popular Science Handbook for Rehabilitation Nursing of Urinary Incontinence After Radical Prostatectomy |
|
|||||
| 5 | 13:28-13:35 |
A Journey Map Study of Health Management in Patients with Pheochromocytoma Undergoing Surgical Treatment |
|
|||||
| 6 | 13:35-13:42 |
Evaluation of the Effect of Stratified Intervention on Pelvic Floor Muscle Exercise Adherence in Postoperative Patients with Prostate Cancer Based on Social Cognitive Theory |
|
|||||
| 7 | 13:42-13:49 |
Clinical Observation of Pelvic Floor Electrical Stimulation Combined with Abdominal Breathing and Manual Massage in the Treatment of Female Pelvic Floor Hypertonicity |
|
|||||
| 8 | 13:49-13:52 |
Discussion and Commentary |
||||||
| 1 | 13:52-13:59 |
Current Status Review and Practical Pathway Exploration of Sexual Health Nursing Services for Perioperative Urological Patients: An Integrative Review |
|
|||||
| 2 | 13:59-14:06 |
A Qualitative Study on the Application of Childlike Popular Science Education Intervention in Medical Fear Among Pediatric Urological Patients |
|
|||||
| 3 | 14:06-14:13 |
Construction and Effect Evaluation of a Specialized Disease Clinic Led by Incontinence Specialist Nurses |
|
|||||
| 4 | 14:13-14:20 |
Effect of Clown Care on Psychological Resilience and Treatment Adherence in Adolescents with Testicular Tumors During the Perioperative Period |
|
|||||
| 5 | 14:20-14:27 |
Defining Sexual Health Using Rodgers' Evolutionary Concept Analysis |
|
|||||
| 6 | 14:27-14:34 |
Construction of a Privacy-Sensitive Follow-Up and Procedure-Specific Functional Rehabilitation Management Model for Andrological Surgery Patients Based on a Large Language Model |
|
|||||
| 7 | 14:34-14:37 |
Discussion and Commentary |
||||||
| 1 | 14:37-14:44 |
A Journey Map Study of Transplantation-Related Health Management in Living-Related Kidney Transplant Recipients |
|
|||||
| 2 | 14:44-14:51 |
A Survey of Anticipatory Grief and Its Influencing Factors in Patients with Bladder Cancer |
|
|||||
| 3 | 14:51-14:58 |
Application of the "Bladder Guardian" Intelligent Platform in Preoperative Decision-Making and Whole-Course Management of Patients with Bladder Cancer |
|
|||||
| 4 | 14:58-15:05 |
Application of the Integrated Physician-Nurse Model in Nursing at a Continence and Pelvic Floor Center Clinic |
|
|||||
| 5 | 15:05-15:12 |
Construction and Empirical Study of an Evidence-Based Nursing-Sensitive Quality Indicator System for Urological Nursing |
|
|||||
| 6 | 15:12-15:19 |
Exploratory Practice of Caregiver-Free Nursing Services in Urological Wards |
|
|||||
| 7 | 15:19-15:22 |
Application and Effect Analysis of an Information Platform-Based Discharge Follow-Up for Patients Undergoing Urological Day Surgery |
|
|||||
| 8 | 15:22-15:25 |
Discussion |
||||||
| 1 | 15:25-15:32 |
Nursing Care of a Patient with Lower Extremity Arterial Ischemia After Ureteroscopic Lithotripsy |
|
|||||
| 2 | 15:32-15:39 |
Study on Dynamic Monitoring of Inflammatory Indicators and Timing of Nursing Intervention in Patients with Urinary Calculi Infection |
|
|||||
| 3 | 15:39-15:46 |
Effect of Precision Nursing Intervention Based on 24-Hour Urinary Stone Risk on Recurrence of Kidney Stones in Patients with Hyperuricemia |
|
|||||
| 4 | 15:46-15:53 |
Nursing Observation of Single-J Ureteral Stent Drainage Through Vesicostomy for Ureteral Stricture Complicated with Vesicovaginal Fistula After Radiotherapy |
|
|||||
| 5 | 15:53-15:59 |
Association Between Preoperative Albumin Levels and Postoperative Venous Thromboembolism After Laparoscopic Urological Surgery: A Correlation Analysis |
|
|||||
| 6 | 15:59-16:06 |
Comprehensive Care and Hospice Care Case Analysis of an Elderly Patient with Delayed Non-Healing Postoperative Urological Wounds Complicated with Heart Failure |
|
|||||
| 7 | 16:06-16:13 |
Analysis of Wound Nursing in 25 Cases of Extramammary Paget's Disease of the Penis and Scrotum After Extended Resection Combined with Transfer Flap Plasty |
|
|||||
| 8 | 16:13-16:16 |
Discussion and Commentary |
||||||
| 1 | 16:16-16:23 |
Application Value of the DeepSeek-R1 Model in Health Education for Healthy Childbearing and Childrearing in Urology |
|
|||||
| 2 | 16:23-16:30 |
Evaluation of the Application of a Urology Nursing Specialty Large Language Model in Patient Health Education and Risk Identification |
|
|||||
| 3 | 16:30-16:37 |
The Authentic Voices of Patients After Radical Prostatectomy: A Sentiment Analysis and Topic Modeling Study Based on Chinese Social Media Texts |
|
|||||
| 4 | 16:37-16:44 |
Effect of DeepSeek-Empowered Situational Health Education in Perioperative Urological Patients |
|
|||||
| 5 | 16:44-16:51 |
Development and Application of a Full-Cycle Management System for Patients with Indwelling Ureteral Stents Driven by Multimodal Data |
|
|||||
| 6 | 16:51-16:58 |
Application of a "Prevention-Control-Nursing" Digital Health Management Model Based on the Symptom Science Model in Bladder Instillation-Induced Irritative Symptoms |
|
|||||
| 7 | 16:58-17:05 |
|
|
|||||
| 8 | 17:05-17:15 |
Summary |
|
|||||
| 1 | 07:50-07:55 |
Opening Remarks |
|
|||||
| 2 | 07:55-08:05 |
Long‑term follow‑up of robotic surgery for high‑risk neuropathic bladder. |
|
|||||
| 3 | 08:05-08:15 |
Proximal Hypospadias: Which Repair is The Best? |
|
|||||
| 4 | 08:15-08:25 |
Mechanism of vesicoureteral reflux Revisited: High Pressure vs. Low Flow |
|
|||||
| 5 | 08:25-08:35 |
When pediatric patients become adults: what you should know |
|
|||||
| 6 | 08:35-08:45 |
Reducing Surgeries in Vesicoureteral Reflux, An experience in Taiwan |
|
|||||
| 1 | 08:45-08:51 |
Innovative Diagnosis and Treatment of Pediatric Urological Diseases |
|
|||||
| 2 | 08:51-08:57 |
Potential Residual Problems When Complex Hypospadias Is Managed as Simple Hypospadias |
|
|||||
| 3 | 08:57-09:03 |
Advances in Umbilical Cord Mesenchymal Stem Cell Exosomes for Alleviating Renal Fibrosis |
|
|||||
| 4 | 09:03-09:09 |
Value of the Anteroposterior Renal Pelvic Diameter in Predicting Surgery for Fetal and Postnatal UPJO with Hydronephrosis |
|
|||||
| 5 | 09:09-09:15 |
Outcomes of Conventional Laparoscopic versus Robot-Assisted Redo Pyeloplasty for Recurrent Obstruction after Pediatric Pyeloplasty |
|
|||||
| 6 | 09:15-09:21 |
Robot-Assisted Enterocystoplasty and Continent Catheterizable Channel Reconstruction |
|
|||||
| 1 | 09:22-09:25 |
Diagnosis and Treatment of Lower-Moiety Ureteropelvic Junction Obstruction in Children with Incomplete Duplex Kidneys |
|
|||||
| 2 | 09:25-09:28 |
Preliminary Application of a Hybrid Technique for Pediatric UPJO with Ipsilateral Ureterovesical Junction Obstruction |
|
|||||
| 3 | 09:28-09:31 |
Clinical Value of Laparoscopic Peritoneal Dialysis Catheter Placement Combined with Subtotal Omentectomy in Children with End-Stage Kidney Disease |
|
|||||
| 4 | 09:31-09:34 |
Multicenter Experience with Laparoscopic and Robot-Assisted Surgery for Recurrent Pediatric Ureteropelvic Junction Obstruction |
|
|||||
| 5 | 09:34-09:37 |
Clinical Experience in the Diagnosis and Treatment of Pediatric Renal Abscess |
|
|||||
| 6 | 09:37-09:40 |
Clinical Phenotypes and Outcomes of Robot-Assisted Laparoscopic Pyeloplasty for Prenatally Detected versus Symptomatic Pediatric UPJO |
|
|||||
| 7 | 09:40-09:43 |
Risk Factors for Urinary Tract Infection after Laparoscopic Pyeloplasty in Preschool Children |
|
|||||
| 8 | 09:43-09:46 |
Robot-Assisted Laparoscopic Extravesical Ureteral Reimplantation for Duplex Kidneys in Children |
|
|||||
| 1 | 09:47-09:50 |
Illustrated Report of Pneumovesicoscopic Bilateral Antireflux Reimplantation for VUR after Bladder Exstrophy-Epispadias Repair |
|
|||||
| 2 | 09:50-09:53 |
Efficacy and Safety of High-Dose Vitamin D Combined with an Enuresis Alarm for Primary Monosymptomatic Nocturnal Enuresis: A Randomized Controlled Trial |
|
|||||
| 3 | 09:53-09:56 |
Minimally Invasive Treatment of Vesicoureteral Reflux with Ipsilateral Middle or Distal Ureteral Obstruction: Video Presentation |
|
|||||
| 4 | 09:56-09:59 |
Sacral Neuromodulation for Pediatric Neurogenic Bladder: Experience from Qilu Hospital |
|
|||||
| 5 | 09:59-10:02 |
Laparoscopic Lich-Gregoir Procedure for Primary Vesicoureteral Reflux in Infants and Young Children |
|
|||||
| 6 | 10:02-10:05 |
Videourodynamic Characteristics of Voiding Dysfunction in Children with Spinal Cord Injuries at Different Levels |
|
|||||
| 7 | 10:05-10:08 |
Cold-Knife versus Holmium Laser Ablation for Posterior Urethral Valves in Children |
|
|||||
| 8 | 10:08-10:11 |
Urodynamic Evidence of Postoperative Obstruction Mediated by Bladder Neck Dysfunction in Children with Posterior Urethral Valves |
|
|||||
| 1 | 10:12-10:15 |
Comparison of Stone Composition and Clinical Characteristics between Tibetan and Non-Tibetan Children with Urolithiasis in Western China |
|
|||||
| 2 | 10:15-10:18 |
Development and Validation of a Nomogram for Predicting Pathogenic Gene Variants in Pediatric Urolithiasis: A Genotype-Phenotype Association Study |
|
|||||
| 3 | 10:18-10:21 |
Outcomes of Transurethral Cystolithotripsy for Pediatric Bladder Stones: More Than Ten Years of Single-Center Experience |
|
|||||
| 4 | 10:21-10:24 |
Analysis of Genetic Features and Genotype-Phenotype Relationships in Patients with Adenine Phosphoribosyltransferase Deficiency |
|
|||||
| 5 | 10:24-10:27 |
Untargeted Fecal Metabolomics Reveals Key Metabolic Disturbances and Potential Biomarkers of Pediatric Urolithiasis in a High-Incidence Area of Xinjiang |
|
|||||
| 6 | 10:27-10:30 |
Analysis of Genotypes and Clinical Phenotypes in Patients with Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency and Urolithiasis or Nephrocalcinosis |
|
|||||
| 1 | 10:31-10:34 |
Rethinking Minimally Invasive Treatment Options for Pediatric Upper Urinary Tract Stones: A Single-Center Real-World Study of More Than Eight Years |
|
|||||
| 2 | 10:34-10:37 |
Flexible-Tip Negative-Pressure Suction Sheath with a Disposable Ultra-Slim Flexible Ureteroscope versus Super-Mini Percutaneous Nephrolithotomy for Pediatric Upper Urinary Tract Stones |
|
|||||
| 3 | 10:37-10:40 |
Does an Antireflux Ureteral Stent Benefit Children after Endoscopic Surgery for Upper Urinary Tract Stones? A Single-Center Randomized Controlled Trial |
|
|||||
| 4 | 10:40-10:43 |
Microperc in the Direct Prone Position for Renal Stones in Young Children: A Retrospective Analysis of 46 Cases |
|
|||||
| 5 | 10:43-10:46 |
Albumin-Corrected Anion Gap Is Associated with Reduced Renal Function at Admission in Children with Urolithiasis: A Retrospective Cohort Study |
|
|||||
| 1 | 10:47-10:50 |
Clinicopathological Characteristics and Survival Outcomes of 501 Pediatric Renal Tumors: A 15-Year Single-Center Retrospective Cohort Study |
|
|||||
| 2 | 10:50-10:53 |
Clinical Application of Laparoscopy for Pediatric Adrenal Masses |
|
|||||
| 3 | 10:53-10:56 |
Management of a Giant Left Wilms Tumor Complicated by Abdominal Compartment Syndrome |
|
|||||
| 4 | 10:56-10:59 |
Robot-Assisted Partial Cystectomy Combined with Ureteral Reimplantation for a Complex Bladder Pheochromocytoma: A Case Report |
|
|||||
| 5 | 10:59-11:02 |
Myeloid AMPK Promotes Cisplatin-Associated Renal Fibrosis by Driving Renal-Resident Macrophage Differentiation through Jun |
|
|||||
| 6 | 11:02-11:05 |
Disulfiram Alleviates Calcium Oxalate-Induced Renal Injury and Crystal Deposition through Inhibition of GSDMD-Mediated Pyroptosis |
|
|||||
| 7 | 11:05-11:08 |
EEF1A2 Drives Immunotherapy Resistance in High-Risk Neuroblastoma by Activating the MUC1-Mediated Tryptophan Metabolism Pathway |
|
|||||
| 1 | 11:08-11:11 |
Preliminary Application of Robot-Assisted Laparoscopy in Pediatric Lower Urinary Tract Reconstruction |
|
|||||
| 2 | 11:11-11:14 |
Outcomes and Postoperative Infections after Robot-Assisted Laparoscopic Buccal Mucosal and Appendiceal Ureteroplasty for Complex Upper Urinary Tract Obstruction in Children |
|
|||||
| 3 | 11:14-11:17 |
Robot-Assisted Spiral-Flap Pyeloplasty for Complex Ureteropelvic Junction Obstruction and Ureteral Atresia |
|
|||||
| 4 | 11:17-11:20 |
Comparison of Robot-Assisted and Laparoscopic Pyeloplasty for Primary Pediatric Ureteropelvic Junction Obstruction: A Retrospective Multicenter Study |
|
|||||
| 5 | 11:20-11:23 |
Robot-Assisted Laparoscopic Appendiceal-Flap versus Lingual Mucosal Graft Ureteroplasty for Long-Segment Ureteral Strictures in Children |
|
|||||
| 1 | 11:24-11:27 |
Proximal Spermatic Vein Reflux-Guided Surgical Selection and Outcomes for Adolescent Nutcracker Syndrome with Varicocele |
|
|||||
| 2 | 11:27-11:30 |
Three-Dimensional or Robot-Assisted Sacral Neuromodulation for Sacral Developmental Abnormalities in Children |
|
|||||
| 3 | 11:30-11:33 |
Outcomes of the Watering Can Holmium Laser Puncture Technique for Duplex Kidney with Distal Ureterocele |
|
|||||
| 4 | 11:33-11:36 |
A Deep Learning-Based Dynamic Multi-Image Weighted Voiding Cystourethrography Model for Automated Detection and Diagnosis of Urinary Tract Anomalies |
|
|||||
| 5 | 11:36-11:39 |
Indocyanine Green Fluorescence-Guided Transumbilical Three-Port Lymphatic-Sparing Modified Palomo Procedure versus Conventional Laparoscopic Palomo Procedure for Pediatric Varicocele |
|
|||||
| 6 | 11:39-11:42 |
Clinical Application and Initial Experience of Robot-Assisted Laparoscopic Renal Autotransplantation in Children |
|
|||||
| 1 | 11:43-11:46 |
Outcomes of One-Stage Penile Advancement for Severe Hypospadias with Penoscrotal Transposition |
|
|||||
| 2 | 11:46-11:49 |
Considerations for Sex Assignment in 46,XX Testicular or Ovotesticular Differences of Sex Development |
|
|||||
| 3 | 11:49-11:52 |
Longitudinal Tubularized Depressed-Flap Urethroplasty for Urethral Defects after Multiple Operations |
|
|||||
| 4 | 11:52-11:55 |
Outcomes of a Modified Mitchell Procedure with Distal Urethral Plate Preservation for Male Epispadias |
|
|||||
| 5 | 11:55-11:58 |
Surgical Strategies for Repairing Different Types of Urethrocutaneous Fistula after Pediatric Hypospadias Surgery |
|
|||||
| 6 | 11:58-12:01 |
Interposition Urethroplasty versus Longitudinally Incised Duckett Urethroplasty for Moderate-to-Severe Penile Curvature |
|
|||||
| 7 | 12:01-12:04 |
Preliminary Outcomes of Tunica Albuginea Incision for Severe Penile Curvature in Children |
|
|||||
| 8 | 12:04-12:07 |
Development and Clinical Outcomes of a Classification-Based Treatment Strategy for Urethral Stricture after Hypospadias Repair |
|
|||||
| 9 | 12:07-12:10 |
Changes in Testicular Volume after Enucleation of Benign Testicular Tumors in Children: A Retrospective Analysis |
|
|||||
| 10 | 12:10-12:13 |
Use of Scrotal Flaps for Residual Penile Curvature after Hypospadias Repair |
|
|||||
| 11 | 12:13-12:16 |
Perioperative Androgen Replacement Improves Outcomes after Anterior Urethroplasty for Hypospadias: Insights from a Preclinical Rabbit Model |
|
|||||
| 12 | 12:16-12:19 |
China's First Exploration of Unilateral Partial Orchiectomy for Fertility Preservation in a Prepubertal Boy |
|
|||||
| 1 | 12:20-12:23 |
Artificial Intelligence-Assisted Continuing Home Care after Laparoscopic Surgery for Long-Term Management of Pediatric Neurogenic Bladder |
|
|||||
| 2 | 12:23-12:26 |
Effects of Family-Centered Perioperative Nursing on Postoperative Pain and Complications in Children with Hypospadias |
|
|||||
| 3 | 12:26-12:29 |
Effects of IMB Model-Based Empowerment Health Education on Parental Caregiving Behaviors and Postoperative Complications in Children with Concealed Penis |
|
|||||
| 4 | 12:29-12:32 |
Application of Three-Dimensional Collaborative Family Empowerment Nursing within an ERAS Pathway for Pediatric Hypospadias |
|
|||||
| 1 | 13:00-13:15 |
Opening Remarks |
|
||||||||
| 1 | 13:15-13:25 |
Prognostic Valuation of Automated CT-Based Body Composition Analysis in First-line Metastatic Renal Cell Carcinoma |
|
||||||||||||||||||||
| 2 | 13:25-13:35 |
Telesurgery in Urology: From Proof-of-Concept to Clinical Reality |
|
||||||||||||||||||||
| 3 | 13:35-13:45 |
Modern imaging in kidney cancer surgery |
|
||||||||||||||||||||
| 4 | 13:45-13:55 |
Applications of artificial intelligence and augmented reality in urology |
|
||||||||||||||||||||
| 5 | 13:55-14:10 |
Discussion |
|
||||||||||||||||||||
| 1 | 14:10-14:20 |
From Clinical Questions to Intelligent Systems: Building AI Research from Everyday Urologic Practice - The Straubing Experience |
|
||||||||||||||||||||
| 2 | 14:20-14:30 |
From Images to Impact: How AI Is Rebuilding the Prostate Cancer Care |
|
||||||||||||||||||||
| 3 | 14:30-14:40 |
AI in Urinary Stone Management - A game changer? |
|
||||||||||||||||||||
| 4 | 14:40-14:50 |
High acuity ultrasound diagnosis and focal ablation of prostate cancers |
|
||||||||||||||||||||
| 5 | 14:50-15:05 |
Discussion |
|
||||||||||||||||||||
| 1 | 15:05-15:15 |
Artificial Intelligence-assisted Robotic Laparoscopic Radical Prostatectomy for Prostate Cancer with Special Morphology |
|
||||||||||||||||||||
| 2 | 15:15-15:25 |
Application of Multimodal Deep Learning Model Deep-PCa in Imaging Diagnosis of Prostate Cancer |
|
||||||||||||||||||||
| 3 | 15:25-15:35 |
Diagnostic Performance of Artificial Intelligence-Assisted Prostate Biopsy Planning Software for Lesion Detection on Multiparametric MRI: A Randomized Crossover Trial |
|
||||||||||||||||||||
| 4 | 15:35-15:45 |
Application of Augmented Reality (AR) Intraoperative Navigation Technology in Robot-Assisted Partial Nephrectomy (RAPN) |
|
||||||||||||||||||||
| 5 | 15:45-16:00 |
Discussion |
|
||||||||||||||||||||
| 1 | 16:00-16:10 |
Development and External Validation of a Multimodal Deep Learning Model for Postoperative Recurrence Risk Stratification in High-Risk Prostate Cancer after Robot-Assisted Radical Prostatectomy |
|
||||||||||||||||||||
| 2 | 16:10-16:20 |
Multimodal Prediction Model for Bladder Cancer Recurrence Under Interval Censoring Based on Vision-Large Language Model |
|
||||||||||||||||||||
| 3 | 16:20-16:30 |
Preliminary Application of an Intelligent Precision Laser Surgical System for Prostate |
|
||||||||||||||||||||
| 4 | 16:30-16:40 |
Prediction of Long-term Renal Function and Risk Stratification after Radical Nephrectomy for Renal Cell Carcinoma Based on Multimodal Deep Learning Model |
|
||||||||||||||||||||
| 5 | 16:40-16:50 |
A Dual-Center Study of Predicting Spatial Protein Expression and Final Surgical Pathology of Urological Tumors by AI-Based Fusion of Preoperative Imaging and Pathological Features |
|
||||||||||||||||||||
| 6 | 16:50-17:05 |
Discussion |
|
||||||||||||||||||||
| 1 | 17:05-17:15 |
UroPACE: Development and Preliminary Clinical Deployment of a Real-time Segmentation Model for Key Anatomical Structures in Minimally Invasive Upper Urinary Tract Surgery |
|
||||||||||||||||||||
| 2 | 17:15-17:25 |
Clinical Value of Early Surgical Intervention for Urinary Sepsis-Associated Acute Kidney Injury Guided by the RAPID-AKI Model |
|
||||||||||||||||||||
| 3 | 17:25-17:35 |
Ultra-inert NIR-II Fluorescent Navigation Dyes for Clinical Translation — Experience Sharing from Nature Photonics |
|
||||||||||||||||||||
| 4 | 17:35-17:45 |
Electromagnetic Navigation Combined with AI Image Fusion-Guided Nanoknife Ablation for Low- and Intermediate-Risk Localized Prostate Cancer: A Single-Center Experience |
|
||||||||||||||||||||
| 5 | 17:45-18:00 |
Discussion |
|
||||||||||||||||||||
| 6 | 18:00-18:10 |
Summary |
|
||||||||||||||||||||
| 1 | 13:30-13:40 |
Opening Remarks |
|
|||||
| 1 | 13:40-13:48 |
Preclinical Evaluation of the Efficacy and Safety of a Drug-Coated Balloon Catheter for Prostatic Dilation in a Canine Model |
|
||||||||||||||
| 2 | 13:48-13:56 |
Development of an Intelligent Navigation System for Transurethral Prostate Surgery Based on Deep Learning |
|
||||||||||||||
| 3 | 13:56-14:04 |
Development and Application of a Large Language Model-Based Follow-up System for Benign Prostatic Hyperplasia |
|
||||||||||||||
| 4 | 14:04-14:12 |
A Two-Pronged Approach: Sonodynamic Therapy for Benign Prostatic Hyperplasia Based on a Copper–Manganese Co-Doped Mesoporous Silica Nanoplatform |
|
||||||||||||||
| 5 | 14:12-14:20 |
Construction of a Tissue-Engineered Bladder with Neural and Vascular Networks Using Conductive Microgel Bioink and 3D Bioprinting |
|
||||||||||||||
| 6 | 14:20-14:28 |
Validation of a Multi-Agent Large Language Model Collaboration Framework for Multidisciplinary Decision-Making in Complex Prostate Diseases |
|
||||||||||||||
| 7 | 14:28-14:48 |
Discussion |
|
||||||||||||||
| 1 | 14:48-14:56 |
Combined Use of PSA Kinetics and MRI for Diagnosing Persistent Prostate Cancer After Irreversible Electroporation |
|
||||||||||||||
| 2 | 14:56-15:04 |
Preliminary Analysis of the Clinical Feasibility and Accuracy of Mercury Robot-Assisted Transperineal Targeted Prostate Biopsy |
|
||||||||||||||
| 3 | 15:04-15:12 |
Machine Learning-Assisted Artificial Olfaction Colorimetric Sensor Array for Urinary Volatile Organic Compound Detection and Noninvasive Bladder Cancer Screening |
|
||||||||||||||
| 4 | 15:12-15:20 |
Development of a Multifunctional Magnetically Controlled Drug-Loading and Sustained-Release Capsule Robot for Bladder Applications |
|
||||||||||||||
| 5 | 15:20-15:28 |
Development of a Large Language Model-Based Prognostic Knowledge Graph and Question-Answering System for Upper Tract Urothelial Carcinoma |
|
||||||||||||||
| 6 | 15:28-15:36 |
Artificial Intelligence-Enabled Full-Cycle Management of Prostate Cancer: Design and Implementation of a Large Language Model-Based Agent |
|
||||||||||||||
| 7 | 15:36-15:56 |
Discussion |
|
||||||||||||||
| 1 | 15:56-16:04 |
Blood-Triggered Adhesive Hydrogel Loaded with Reactive Oxygen Species-Responsive Liposomes for the Treatment of Acute Kidney Injury |
|
||||||||||||||
| 2 | 16:04-16:12 |
Design and Performance Validation of a Poly(amino acid)-Coated Ureteral Stent for Inhibiting Protein Adhesion and Stent Encrustation |
|
||||||||||||||
| 3 | 16:12-16:20 |
Quantitative Evaluation of Ureteral Stent Encrustation, Identification of High-Risk Deposition Sites, and Engineering Optimization Strategies for Encrustation-Resistant Stents |
|
||||||||||||||
| 4 | 16:20-16:28 |
DLP 3D Bioprinted Bionic Bladder Patch Based on Photo-Crosslinkable Bladder Acellular Matrix Hydrogel for Bladder Defect Repair and Angiogenesis Promotion |
|
||||||||||||||
| 5 | 16:28-16:36 |
A Methacryloyloxyethyl Phosphorylcholine Polymer Coating Effectively Inhibits Surface Biofouling of Ureteral Stents During Long-Term Indwelling |
|
||||||||||||||
| 6 | 16:36-16:44 |
Subgroup Analysis of Long-Term Outcomes of Artificial Urinary Sphincter Implantation for Stress Urinary Incontinence |
|
||||||||||||||
| 7 | 16:44-17:04 |
Discussion |
|
||||||||||||||